• Oncogenetic pedigrees: Relation between design and ability to predict mutation.
    • Kwiatkowski F, Serlet L, Stos A.
    • Biosystems. 2023 Feb 4:104841. doi: 10.1016/j.biosystems.2023.104841. Epub ahead of print.
    • Development of an EHR-integrated electronic tool for the identification of individuals at-risk for an inherited cancer syndrome. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Singh V, Rafter T, Sharbatji M, Brierley K, Healy C, Liu J, Brown Q, Xicola R, Kashyap N, Llor X.
    • Fam Cancer. [O-06: Research Categories» Lynch syndrome.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Innovative approaches to expanding cancer genetic testing in Michigan (project might). [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Stoffel EM, Austin S, Koeppe E, Hanson EN, Delacroix E, Rizzo E, Griggs JJ, Resnicow K.
    • Fam Cancer. [P-17: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Implementation of a multi modal best practice bundle to improve genetic testing referral for pancreatic cancer patients. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Blazey M, Lee T, Hendershot A, Bartell N, Marino D.
    • Fam Cancer. [P-20: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Performance of INHERET® risk assessment tool for identifying pathogenic germline variants among individuals referred for cancer genetics evaluation. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Henry ML, Pialtos K, Fry S, Koeppe E, Osborne J, Cook A, Hulswitt B, Milliron KJ, Merajver S, Stoffel E.
    • Fam Cancer. [P-21: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Assessing Breast and Ovarian Cancer Risk Prior to Gender-Affirming Surgery.
    • Cortina CS.
    • JAMA Surg. 2023 Jan 11. doi: 10.1001/jamasurg.2022.5447. Epub ahead of print.
    • Commentary
    • Performance of risk prediction models in breast cancer screening among women in Cyprus.
    • Danladi C, Serakinci N.
    • East Mediterr Health J. 2022 Dec 21;28(12):888-895. doi: 10.26719/emhj.22.089.
    • CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer.
    • Nyberg T, Brook MN, Ficorella L, Lee A, Dennis J, Yang X, Wilcox N, Dadaev T, Govindasami K, Lush M, Leslie G, Lophatananon A, Muir K, Bancroft E, Easton DF, Tischkowitz M, Kote-Jarai Z, Eeles R, Antoniou AC.
    • J Clin Oncol. 2022 Dec 9:JCO2201453. doi: 10.1200/JCO.22.01453. Epub ahead of print.

    Related:

    •• Press: Tool Accurately Predicts Risk of Developing Prostate Cancer. (Inside Precision Medicine)

    • Investigating the presentation of uncertainty in an icon array: A randomized trial.
    • Recchia G, Lawrence ACE, Freeman ALJ.
    • PEC Innov. 2022 Dec;1:None. doi: 10.1016/j.pecinn.2021.100003.
    • Differential involvement of germline pathogenic variants in breast cancer genes between DCIS and low-grade invasive cancers.
    • Evans DG, Sithambaram S, van Veen EM, Burghel GJ, Schlecht H, Harkness EF, Byers H, Ellingford JM, Gandhi A, Howell SJ, Howell A, Forde C, Lalloo F, Newman WG, Smith MJ, Woodward ER.
    • J Med Genet. 2022 Nov 28:jmg-2022-108790. doi: 10.1136/jmg-2022-108790. Epub ahead of print.
    • Halo Diagnostics, Ikonopedia Partner to Provide Genetic Testing for Breast Cancer.
    • [No author given]
    • Precision Oncology News. 2022 Nov 28.
    • UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.
    • Hanson H, Kulkarni A, Loong L, Kavanaugh G, Torr B, Allen S, Ahmed M, Antoniou AC, Cleaver R, Dabir T, Evans DG, Golightly E, Jewell R, Kohut K, Manchanda R, Murray A, Murray J, Ong KR, Rosenthal AN, Woodward ER, Eccles DM, Turnbull C, Tischkowitz M; Consensus meeting attendees, Lalloo F.
    • J Med Genet. 2022 Nov 21:jmg-2022-108898. doi: 10.1136/jmg-2022-108898. Epub ahead of print.
    • Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service.
    • Matta BP, Gomes R, Mattos D, Olicio R, Nascimento CM, Ferreira GM, Brant AC, Boroni M, Furtado C, Lima V, Moreira MÂM, Dos Santos ACE.
    • Sci Rep. 2022 Nov 3;12(1):18629. doi: 10.1038/s41598-022-23012-3.
    • Clinical application of artificial neural network (ANN) modeling to predict BRCA1/2 germline deleterious variants in Chinese bilateral primary breast cancer patients.
    • Li Y, Chen L, Lv J, Chen X, Zeng B, Chen M, Guo W, Lin Y, Yu L, Hou J, Li J, Zhou P, Zhang W, Li S, Jin X, Cai W, Zhang K, Huang Y, Wang C, Fu F.
    • BMC Cancer. 2022 Nov 2;22(1):1125. doi: 10.1186/s12885-022-10160-y.
    • Who Should Have Multigene Germline Testing for Hereditary Cancer?
    • Savage SA.
    • J Clin Oncol. 2022 Sep 27:JCO2201691. doi: 10.1200/JCO.22.01691. Epub ahead of print.

    Related:

    Original research:

    Development and Validation of the PREMMplus Model for Multigene Hereditary Cancer Risk Assessment.

    • Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence.
    • Lee A, Mavaddat N, Cunningham A, Carver T, Ficorella L, Archer S, Walter FM, Tischkowitz M, Roberts J, Usher-Smith J, Simard J, Schmidt MK, Devilee P, Zadnik V, Jürgens H, Mouret-Fourme E, De Pauw A, Rookus M, Mooij TM, Pharoah PP, Easton DF, Antoniou AC.
    • J Med Genet. 2022 Sep 26:jmedgenet-2022-108471. doi: 10.1136/jmedgenet-2022-108471. Epub ahead of print.
    • Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study.
    • Yang X, Eriksson M, Czene K, Lee A, Leslie G, Lush M, Wang J, Dennis J, Dorling L, Carvalho S, Mavaddat N, Simard J, Schmidt MK, Easton DF, Hall P, Antoniou AC.
    • J Med Genet. 2022 Sep 26:jmg-2022-108806. doi: 10.1136/jmg-2022-108806. Epub ahead of print.
    • Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.
    • Whitworth PW, Beitsch PD, Patel R, Rosen B, Compagnoni G, Baron PL, Simmons R, Brown EA, Gold L, Holmes D, Smith LA, Kinney M, Grady I, Clark P, Barbosa K, Lyons S, Riley L, Coomer C, Curcio L, Ruiz A, Khan S, MacDonald H, Hughes K, Hardwick MK, Heald B, Munro SB, Nielsen SM, Esplin ED.
    • JAMA Netw Open. 2022 Sep 1 [2022 Sep 22];5(9):e2232787. doi: 10.1001/jamanetworkopen.2022.32787.

    Related:

    Research news: Universal Genetic Testing in Breast Cancer Further Supported in New Invitae-Led Study. (GenomeWeb)

    Research news: Time for Universal Germline Genetic Testing in Breast Cancer. (Medscape)

    • Breast cancer risk reduction: who, why, and what?
    • Bozzuto LM.
    • Best Pract Res Clin Obstet Gynaecol. 2022 Sep;83:36-45. doi: 10.1016/j.bpobgyn.2021.11.012. Epub 2021 Dec 8.
    • Review
    • Leveraging an Informatics Approach to Identify an Unmet Clinical Need for BRCA1/2 Testing Among Patients With Ovarian Cancer.
    • Gray SW, Ottesen RA, Currey M, Cristea M, Nikowitz J, Shehayeb S, Lozano V, Hom J, Kilburn J, Lopez LN, Wing S, Sosa E, Shen J, Morris M, Dilsizian B, Joseph T, Shen J, Adeimy C, Phillips T, Bahadini B, Niland JC.
    • JCO Clin Cancer Inform. 2022 Sep;6:e2200034. doi: 10.1200/CCI.22.00034.
    • Online Tool IDs People With Genetic Mutations Linked to Cancer.
    • Brooks M.
    • Medscape Oncology. 2022 Aug 30.

    Related:

    Original research:

    Development and Validation of the PREMMplus Model for Multigene Hereditary Cancer Risk Assessment.

    • Estimating lifetime risk for breast cancer as a screening tool for identifying those who would benefit from additional services among women utilizing mobile mammography.
    • Wetmore JB, Otarola L, Paulino LJ, Henry BR, Levine AF, Kone D, Ulloa J, Jandorf L, Margolies L, Vang S.
    • J Cancer Policy. 2022 Aug 19:100354. doi: 10.1016/j.jcpo.2022.100354. Epub ahead of print.
    • Development and Validation of the PREMMplus Model for Multigene Hereditary Cancer Risk Assessment.
    • Yurgelun MB, Uno H, Furniss CS, Ukaegbu C, Horiguchi M, Yussuf A, LaDuca H, Chittenden A, Garber JE, Syngal S.
    • J Clin Oncol. 2022 Aug 12:JCO2200120. doi: 10.1200/JCO.22.00120. Epub ahead of print.

    Related:

    Commentary:

    Who Should Have Multigene Germline Testing for Hereditary Cancer?

    Research news: Online Tool IDs People With Genetic Mutations Linked to Cancer. (Medscape Oncology)

    • Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluation.
    • Menko FH, Monkhorst K, Hogervorst FBL, Rosenberg EH, Adank M, Ruijs MWG, Bleiker EMA, Sonke GS, Russell NS, Oldenburg HSA, van der Kolk LE.
    • Crit Rev Oncol Hematol. 2022 Aug;176:103642. doi: 10.1016/j.critrevonc.2022.103642. Epub 2022 Mar 5.
    • An Electronic Health Record Tool Increases Genetic Counseling Referral of Individuals at Hereditary Cancer Risk: An Intervention Study.
    • Wurtmann EJ, Baldinger S, Olet S, Daley A, Swenson KK.
    • Public Health Genomics. 2022 Jul 27:1-7. doi: 10.1159/000525447. Epub ahead of print.
    • Germline Testing in a Cohort of Patients at High Risk of Hereditary Cancer Predisposition Syndromes: First Two-Year Results from South Italy.
    • Paduano F, Colao E, Fabiani F, Rocca V, Dinatolo F, Dattola A, D'Antona L, Amato R, Trapasso F, Baudi F, Perrotti N, Iuliano R.
    • Genes (Basel). 2022 Jul 21;13(7):1286. doi: 10.3390/genes13071286.
    • Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial.
    • Kukafka R, Pan S, Silverman T, Zhang T, Chung WK, Terry MB, Fleck E, Younge RG, Trivedi MS, McGuinness JE, He T, Dimond J, Crew KD.
    • JAMA Netw Open. 2022 Jul 18;5(7):e2222092. doi: 10.1001/jamanetworkopen.2022.22092.

    Related:

    Identifier: NCT03470402: Decision Support for BRCA Testing in Ethnically Diverse Women. (ClinicalTrials.gov)

    • Brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed non-serous, non-mucinous ovarian cancers.
    • Kim SR, Tone A, Kim R, Cesari M, Clarke B, Hart T, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, Ferguson SE, Eiriksson L.
    • Int J Gynecol Cancer. 2022 Jul 4;32(7):891-898. doi: 10.1136/ijgc-2021-003082.
    • Genetic clinicians' confidence in BOADICEA comprehensive breast cancer risk estimates and counselees' psychosocial outcomes: a prospective study.
    • Brédart A, De Pauw A, Tüchler A, Lakeman IMM, Anota A, Rhiem K, Schmutzler R, van Asperen CJ, Devilee P, Stoppa-Lyonnet D, Kop JL, Dolbeault S.
    • Clin Genet. 2022 Jul;102(1):30-39. doi: 10.1111/cge.14147. Epub 2022 May 16.
    • Identification of women at risk of hereditary breast-ovarian cancer among participants in a population-based breast cancer screening.
    • Bonelli L, Valle I, Rebora I, Ricci P, Biocchi L, Bruschi G, Parodi S, Bruzzone C, Varesco L.
    • Fam Cancer. 2022 Jul;21(3):309-318. doi: 10.1007/s10689-021-00281-x. Epub 2021 Oct 20.
    • Breast cancer risk stratification in women of screening age: Incremental effects of adding mammographic density, polygenic risk, and a gene panel.
    • Evans DGR, van Veen EM, Harkness EF, Brentnall AR, Astley SM, Byers H, Woodward ER, Sampson S, Southworth J, Howell SJ, Maxwell AJ, Newman WG, Cuzick J, Howell A.
    • Genet Med. 2022 Jul;24(7):1485-1494. doi: 10.1016/j.gim.2022.03.009. Epub 2022 Apr 15.
    • Polygenic risk score as a possible tool for identifying familial monogenic causes of complex diseases.
    • Lu T, Forgetta V, Richards JB, Greenwood CMT.
    • Genet Med. 2022 Jul;24(7):1545-1555. doi: 10.1016/j.gim.2022.03.022. Epub 2022 Apr 23.
    • Can Automated Alerts in the Electronic Health Record Encourage Referrals for Genetic Counseling and Testing Among Patients at High Risk for Hereditary Cancer Syndromes?
    • Zorn KK, Simonson ME, Faulkner JL, Carr CL, Acuna J, Hall TL, Jenkins JF, Drummond KL, Curran GM.
    • JCO Oncol Pract. 2022 Jul;18(7):e1219-e1224. doi: 10.1200/OP.21.00641. Epub 2022 Mar 22.
    • Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.
    • Liberto JM, Chen SY, Shih IM, Wang TH, Wang TL, Pisanic TR 2nd.
    • Cancers (Basel). 2022 Jun 11;14(12):2885. doi: 10.3390/cancers14122885.
    • Literacy-adapted, electronic family history assessment for genetics referral in primary care: patient user insights from qualitative interviews.
    • Mittendorf KF, Lewis HS, Duenas DM, Eubanks DJ, Gilmore MJ, Goddard KAB, Joseph G, Kauffman TL, Kraft SA, Lindberg NM, Reyes AA, Shuster E, Syngal S, Ukaegbu C, Zepp JM, Wilfond BS, Porter KM.
    • Hered Cancer Clin Pract. 2022 Jun 10;20(1):22. doi: 10.1186/s13053-022-00231-3.

    Related:

    Identifier: NCT03426878: Cancer Health Assessments Reaching Many (CHARM). (ClinicalTrials.gov)

    • Development, Implementation and Initial Results of CDSS Recommendations for Patients at Risk of Hereditary Breast Cancer.
    • Rosa J, Tajerian M, Zin Y, Brunner M, Lopez N, Gaiera A, Butti M, Menazzi S, Chanfreau H, Luna D, Rubin L, Benitez S.
    • Stud Health Technol Inform. 2022 Jun 6;290:340-344. doi: 10.3233/SHTI220092.
    • Clinical tools and counseling considerations for breast cancer risk assessment and evaluation for hereditary cancer risk.
    • Hipp LE, Hulswit BB, Milliron KJ.
    • Best Pract Res Clin Obstet Gynaecol. 2022 Jun;82:12-29. doi: 10.1016/j.bpobgyn.2022.02.001. Epub 2022 Feb 9.
    • Review
    • Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access.
    • Amendola LM, Shuster E, Leo MC, Dorschner MO, Rolf BA, Shirts BH, Gilmore MJ, Okuyama S, Zepp JM, Kauffman TL, Mittendorf KF, Bellcross C, Jenkins CL, Joseph G, Riddle L, Syngal S, Ukaegbu C, Goddard KAB, Wilfond BS, Jarvik GP; CHARM Study.
    • Genet Med. 2022 Jun;24(6):1196-1205. doi: 10.1016/j.gim.2022.02.006. Epub 2022 Mar 16.
    • Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial.
    • Archer S, Fennell N, Colvin E, Laquindanum R, Mills M, Dennis R, Stutzin Donoso F, Gold R, Fan A, Downes K, Ford J, Antoniou AC, Kurian AW, Evans DG, Tischkowitz M.
    • Cancers (Basel). 2022 May 31;14(11):2716. doi: 10.3390/cancers14112716.
    • Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast Cancer.
    • Ang BH, Ho WK, Wijaya E, Kwan PY, Ng PS, Yoon SY, Hasan SN, Lim JMC, Hassan T, Tai MC, Allen J, Lee A, Taib NAM, Yip CH, Hartman M, Lim SH, Tan EY, Tan BKT, Tan SM, Tan VKM, Ho PJ, Khng AJ, Dunning AM, Li J, Easton DF, Antoniou AC, Teo SH.
    • J Clin Oncol. 2022 May 10;40(14):1542-1551. doi: 10.1200/JCO.21.01647. Epub 2022 Feb 10.
    • Assessing Breast Cancer Risks to Improve Care for an Increased-Risk Population within Eastern North Carolina.
    • Shelton CH, Bowen C, Guenther WC, Jordan B, Boehmer LM, Weldon CB, Trosman JR, Ruiz A.
    • N C Med J. 2022 May-Jun;83(3):221-228. doi: 10.18043/ncm.83.3.221.
    • Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification.
    • Ho PJ, Ho WK, Khng AJ, Yeoh YS, Tan BK, Tan EY, Lim GH, Tan SM, Tan VKM, Yip CH, Mohd-Taib NA, Wong FY, Lim EH, Ngeow J, Chay WY, Leong LCH, Yong WS, Seah CM, Tang SW, Ng CWQ, Yan Z, Lee JA, Rahmat K, Islam T, Hassan T, Tai MC, Khor CC, Yuan JM, Koh WP, Sim X, Dunning AM, Bolla MK, Antoniou AC, Teo SH, Li J, Hartman M.
    • BMC Med. 2022 Apr 26;20(1):150. doi: 10.1186/s12916-022-02334-z.
    • Male Breast Cancer: From Molecular Genetics to Clinical Management.
    • Pensabene M, Von Arx C, De Laurentiis M.
    • Cancers (Basel). 2022 Apr 15;14(8):2006. doi: 10.3390/cancers14082006.
    • Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors.
    • Schmutzler RK, Schmitz-Luhn B, Borisch B, Devilee P, Eccles D, Hall P, Balmaña J, Boccia S, Dabrock P, Emons G, Gaissmaier W, Gronwald J, Houwaart S, Huster S, Kast K, Katalinic A, Linn SC, Moorthie S, Pharoah P, Rhiem K, Spranger T, Stoppa-Lyonnet D, van Delden JJM, van den Bulcke M, Woopen C.
    • Breast Care (Basel). 2022 Apr;17(2):208-223. doi: 10.1159/000517182. Epub 2021 Aug 12.
    • Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice.
    • Giri VN, Walker A, Gross L, Trabulsi EJ, Lallas CD, Kelly WK, Gomella LG, Fischer C, Loeb S.
    • Clin Genitourin Cancer. 2022 Apr;20(2):e104-e113. doi: 10.1016/j.clgc.2021.11.009. Epub 2021 Nov 27.
    • 30 year experience of index case identification and outcomes of cascade testing in high-risk breast and colorectal cancer predisposition genes.
    • Woodward ER, Green K, Burghel GJ, Bulman M, Clancy T, Lalloo F, Schlecht H, Wallace AJ, Evans DG.
    • Eur J Hum Genet. 2022 Apr;30(4):413-419. doi: 10.1038/s41431-021-01011-8. Epub 2021 Dec 6.
    • Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future-Five-Years' Single-Institution Experience of 762 Consecutive Patients.
    • Fumagalli C, Betella I, Rappa A, di Giminiani M, Gaiano M, De Vitis LA, Zambetti B, Vacirca D, Multinu F, Venetis K, Colombo N, Barberis M, Guerini Rocco E.
    • Cancers (Basel). 2022 Mar 23;14(7):1638. doi: 10.3390/cancers14071638.
    • BRCA mutations: Implications of genetic testing in ovarian cancer.
    • Talwar V, Rauthan A.
    • Indian J Cancer. 2022 Mar;59(Supplement):S56-S67. doi: 10.4103/ijc.IJC_1394_20.
    • DrABC: deep learning accurately predicts germline pathogenic mutation status in breast cancer patients based on phenotype data.
    • Liu J, Zhao H, Zheng Y, Dong L, Zhao S, Huang Y, Huang S, Qian T, Zou J, Liu S, Li J, Yan Z, Li Y, Zhang S, Huang X, Wang W, Li Y, Wang J, Ming Y, Li X, Xing Z, Qin L, Zhao Z, Jia Z, Li J, Liu G, Zhang M, Feng K, Wu J, Zhang J, Yang Y, Wu Z, Liu Z, Ying J, Wang X, Su J, Wang X, Wu N.
    • Genome Med. 2022 Feb 25;14(1):21. doi: 10.1186/s13073-022-01027-9.
    • BRCA1/2 Mutations in Vietnamese Patients with Hereditary Breast and Ovarian Cancer Syndrome.
    • Le TN, Tran VK, Nguyen TT, Vo NS, Hoang TH, Vo HL, Nguyen TT, Nguyen PD, Nguyen VT, Ta TV, Tran HT.
    • Genes (Basel). 2022 Jan 29;13(2):268. doi: 10.3390/genes13020268.
    • Remote AI Supported E-Multidisciplinary Oncology Conference in Breast Cancer as a Technology and Method to Optimize Outcomes in the Peripheries.
    • Mammas CS, Mamma AS, Papaxoinis G, Georgiou I.
    • Stud Health Technol Inform. 2022 Jan 14;289:309-312. doi: 10.3233/SHTI210921.
    • Special Issue “Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer”.
    • Manchanda R.
    • Cancers (Basel). 2022 Jan 10;14(2):319. doi: 10.3390/cancers14020319.
    • Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    • Arun BK, Peterson SK, Sweeney LE, Bluebond RD, Tidwell RSS, Makhnoon S, Kushwaha AC.
    • Cancer. 2022 Jan 1;128(1):94-102. doi: 10.1002/cncr.33866. Epub 2021 Aug 23.

    Related:

    Editorial:

    Population screening to identify women at risk for hereditary breast cancer syndromes: The path forward or the road not taken?

    • Identifying women with increased risk of breast cancer and implementing risk-reducing strategies and supplemental imaging.
    • Vegunta S, Bhatt AA, Choudhery SA, Pruthi S, Kaur AS.
    • Breast Cancer. 2022 Jan;29(1):19-29. doi: 10.1007/s12282-021-01298-x. Epub 2021 Oct 19.
    • Review
    • Comparison of a Cancer Family History Collection and Risk Assessment Tool - ItRunsInMyFamily - with Risk Assessment by Health-Care Professionals.
    • Ritchie JB, Welch BM, Allen CG, Frey LJ, Morrison H, Schiffman JD, Alekseyenko AV, Dean B, Hughes Halbert C, Bellcross C.
    • Public Health Genomics. 2021 Dec 6:1-9. doi: 10.1159/000520001. Epub ahead of print.
    • Familial Breast Cancer: Disease Related Gene Mutations and Screening Strategies for Chinese Population.
    • Shen L, Zhang S, Wang K, Wang X.
    • Front Oncol. 2021 Dec 1;11:740227. doi: 10.3389/fonc.2021.740227.

    Related:

    Commentary:

    Editorial: Familial Cancer in China: From Detection to Screening and Management.

    • Hereditary Cancer Risk Using a Genetic Chatbot Before Routine Care Visits.
    • Nazareth S, Hayward L, Simmons E, Snir M, Hatchell KE, Rojahn S, Slotnick RN, Nussbaum RL.
    • Obstet Gynecol. 2021 Dec 1;138(6):860-870. doi: 10.1097/AOG.0000000000004596.
    • Information needs on breast cancer genetic and non-genetic risk factors in relatives of women with a BRCA1/2 or PALB2 pathogenic variant.
    • Brédart A, De Pauw A, Anota A, Tüchler A, Dick J, Müller A, Kop JL, Rhiem K, Schmutzler R, Devilee P, Stoppa-Lyonnet D, Dolbeault S.
    • Breast. 2021 Dec;60:38-44. doi: 10.1016/j.breast.2021.08.011. Epub 2021 Aug 23.
    • A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO.
    • Blackford AL, Childs EJ, Porter N, Petersen GM, Rabe KG, Gallinger S, Borgida A, Syngal S, Cote ML, Schwartz AG, Goggins MG, Hruban RH, Parmigiani G, Klein AP.
    • Br J Cancer. 2021 Dec;125(12):1712-1717. doi: 10.1038/s41416-021-01580-x. Epub 2021 Oct 26.
    • Utilization of breast cancer risk prediction models by cancer genetic counselors in clinical practice predominantly in the United States.
    • Park MS, Weissman SM, Postula KJV, Williams CS, Mauer CB, O'Neill SM.
    • J Genet Couns. 2021 Dec;30(6):1737-1747. doi: 10.1002/jgc4.1442. Epub 2021 Jun 2.
    • Universal genetic testing of patients with newly diagnosed breast cancer - ready for prime time?
    • De Silva DL, James PA, Mann GB, Lindeman GJ.
    • Med J Aust. 2021 Nov 15;215(10):449-453. doi: 10.5694/mja2.51317. Epub 2021 Oct 22.
    • Commentary
    • A Review of Breast Cancer Risk Factors in Adolescents and Young Adults.
    • McVeigh UM, Tepper JW, McVeigh TP.
    • Cancers (Basel). 2021 Nov 5;13(21):5552. doi: 10.3390/cancers13215552.
    • MSK Fellows Develop Online Resource to Increase Awareness of Genetic Cascade Testing.
    • Kanski A.
    • Precision Oncology News. Technology. 2021 Oct 21.
    • News
    • Outcomes4Me Incorporates NCCN Hereditary Cancer Risk Testing Guidelines Into Patient-Facing App.
    • [No author given]
    • Precision Oncology News. Disease Areas. 2021 Oct 18.
    • Hereditary Breast and Ovarian Cancer Screening Syndrome Profile in Women Diagnosed with Breast Cancer from Paraná State Southwest.
    • Moura JB, Ghedin CC, Takakura ÉT, Scandolara TB, Rech D, Panis C.
    • Rev Bras Ginecol Obstet. 2021 Aug;43(8):616-621. English. doi: 10.1055/s-0041-1733998. Epub 2021 Sep 21.
    • Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America.
    • Herzog JS, Chavarri-Guerra Y, Castillo D, Abugattas J, Villarreal-Garza C, Sand S, Clague-Dehart J, Alvarez-Gómez RM, Wegman-Ostrosky T, Mohar A, Mora P, Del Toro-Valero A, Daneri-Navarro A, Rodriguez Y, Cruz-Correa M, Ashton-Prolla P, Alemar B, Mejia R, Gallardo L, Shaw R, Yang K, Cervantes A, Tsang K, Nehoray B, Barrera Saldana H, Neuhausen S, Weitzel JN.
    • NPJ Breast Cancer. 2021 Aug 19;7(1):107. doi: 10.1038/s41523-021-00317-6.
    • Breast Cancer Risk Assessment and Primary Prevention Advice in Primary Care: A Systematic Review of Provider Attitudes and Routine Behaviours.
    • Bellhouse S, Hawkes RE, Howell SJ, Gorman L, French DP.
    • Cancers (Basel). 2021 Aug 18;13(16):4150. doi: 10.3390/cancers13164150.
    • Gene Panel Testing for Breast Cancer Reveals Differential Effect of Prior BRCA1/2 Probability.
    • Evans DG, van Veen EM, Woodward ER, Harkness EF, Ellingford JM, Bowers NL, Wallace AJ, Howell SJ, Howell A, Lalloo F, Newman WG, Smith MJ.
    • Cancers (Basel). 2021 Aug 18;13(16):4154. doi: 10.3390/cancers13164154.
    • Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population.
    • Senda N, Kawaguchi-Sakita N, Kawashima M, Inagaki-Kawata Y, Yoshida K, Takada M, Kataoka M, Torii M, Nishimura T, Kawaguchi K, Suzuki E, Kataoka Y, Matsumoto Y, Yoshibayashi H, Yamagami K, Tsuyuki S, Takahara S, Yamauchi A, Shinkura N, Kato H, Moriguchi Y, Okamura R, Kan N, Suwa H, Sakata S, Mashima S, Yotsumoto F, Tachibana T, Tanaka M, Togashi K, Haga H, Yamada T, Kosugi S, Inamoto T, Sugimoto M, Ogawa S, Toi M.
    • Cancer Sci. 2021 Aug;112(8):3338-3348. doi: 10.1111/cas.14986. Epub 2021 Jun 28.
    • A Personal Breast Cancer Risk Stratification Model Using Common Variants and Environmental Risk Factors in Japanese Females.
    • Oze I, Ito H, Kasugai Y, Yamaji T, Kijima Y, Ugai T, Kasuga Y, Ouellette TK, Taniyama Y, Koyanagi YN, Imoto I, Tsugane S, Koriyama C, Iwasaki M, Matsuo K.
    • Cancers (Basel). 2021 Jul 28;13(15):3796. doi: 10.3390/cancers13153796.
    • Volpara Adding Invitae Genetic Test Ordering to Breast Risk Software Platform.
    • [No author given]
    • GenomeWeb. Disease Areas. Cancer. 2021 Jul 22.
    • Evaluation and comparison of hereditary Cancer guidelines in the population.
    • Ritchie JB, Bellcross C, Allen CG, Frey L, Morrison H, Schiffman JD, Welch BM.
    • Hered Cancer Clin Pract. 2021 Jul 17;19(1):31. doi: 10.1186/s13053-021-00188-9.
    • Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
    • Zeng H, Chen L, Zhang M, Luo Y, Ma X.
    • Gynecol Oncol. 2021 Jul 15:S0090-8258(21)00577-1. doi: 10.1016/j.ygyno.2021.07.015. Epub ahead of print.
    • Search Behavior Regarding Cancer Susceptibility Genes Using a Clinical Decision Support Tool for Gene-Specific Penetrance: Content Analysis.
    • Yin K, Zhou J, Singh P, Wang J, Braun D, Hughes KS.
    • JMIR Cancer. 2021 Jul 13;7(3):e28527. doi: 10.2196/28527.
    • Knowledge, views and expectations for cancer polygenic risk testing in clinical practice: a cross-sectional survey of health professionals.
    • Smit AK, Sharman AR, Espinoza D, Wallingford C, Young MA, Dunlop K, Tiller J, Newson AJ, Meiser B, Cust AE, Yanes T.
    • Clin Genet. 2021 Jul 3. doi: 10.1111/cge.14025. Epub ahead of print.
    • A simple framework to identify optimal cost-effective risk thresholds for a single screen: Comparison to Decision Curve Analysis.
    • Katki HA, Bebu I.
    • J R Stat Soc Ser A Stat Soc. 2021 Jul;184(3):887-903. doi: 10.1111/rssa.12680. Epub 2021 Mar 23.
    • Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I).
    • Brooks JD, Nabi HH, Andrulis IL, Antoniou AC, Chiquette J, Després P, Devilee P, Dorval M, Droit A, Easton DF, Eisen A, Eloy L, Fienberg S, Goldgar D, Hahnen E, Joly Y, Knoppers BM, Lofters A, Masson JY, Mittmann N, Paquette JS, Pashayan N, Schmutzler R, Stockley T, Tavtigian SV, Walker MJ, Wolfson M, Chiarelli AM, Simard J.
    • J Pers Med. 2021 Jun 4;11(6):511. doi: 10.3390/jpm11060511.
    • A systematic review of recommendations on screening strategies for breast cancer due to hereditary predisposition: Who, When, and How?
    • Cai Y, Li J, Gao Y, Yang K, He J, Li N, Tian J.
    • Cancer Med. 2021 May;10(10):3437-3448. doi: 10.1002/cam4.3898. Epub 2021 May 1.
    • Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
    • Leon P, Cancel-Tassin G, Bourdon V, Buecher B, Oudard S, Brureau L, Jouffe L, Blanchet P, Stoppa-Lyonnet D, Coulet F, Sobol H, Cussenot O.
    • Prostate. 2021 May;81(6):318-325. doi: 10.1002/pros.24109. Epub 2021 Feb 18.
    • Use of a Standardized Tool to Identify Women at Risk for Hereditary Breast and Ovarian Cancer.
    • Nurs Womens Health. 2021 Apr 29:S1751-4851(21)00080-5. doi: 10.1016/j.nwh.2021.03.008. Epub ahead of print.
    • Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants.
    • Power R, Leavy C, Nolan C, White N, Clarke R, Cadoo KA, Gallagher DJ, Lowery MA.
    • Fam Cancer. 2021 Apr;20(2):97-101. doi: 10.1007/s10689-020-00205-1. Epub 2020 Sep 12.
    • Clinical implementation of an oncology-specific family health history risk assessment tool.
    • Fung SM, Wu RR, Myers RA, Goh J, Ginsburg GS, Matchar D, Orlando LA, Ngeow J.
    • Hered Cancer Clin Pract. 2021 Mar 20;19(1):20. doi: 10.1186/s13053-021-00177-y.
    • Prospective Evaluation of the Addition of Polygenic Risk Scores to Breast Cancer Risk Models.
    • Li SX, Milne RL, Nguyen-Dumont T, Wang X, English DR, Giles GG, Southey MC, Antoniou AC, Lee A, Li S, Winship I, Hopper JL, Terry MB, MacInnis RJ.
    • JNCI Cancer Spectr. 2021 Mar 2;5(3):pkab021. doi: 10.1093/jncics/pkab021.
    • Antidepressants for Older People, Point-of-Care Ultrasonograpy, BRCA Testing, Probiotics.
    • [No author given]
    • Am Fam Physician. 2021 Mar 1;103(5):270.
    • Review
    • Assessing Risk of Breast Cancer: A Review of Risk Prediction Models.
    • Kim G, Bahl M.
    • J Breast Imaging. 2021 Feb 19;3(2):144-155. doi: 10.1093/jbi/wbab001. eCollection Mar-Apr 2021.
    • Review
    • Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.
    • Pal Choudhury P, Brook MN, Hurson AN, Lee A, Mulder CV, Coulson P, Schoemaker MJ, Jones ME, Swerdlow AJ, Chatterjee N, Antoniou AC, Garcia-Closas M.
    • Breast Cancer Res. 2021 Feb 15;23(1):22. doi: 10.1186/s13058-021-01399-7.
    • Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    • Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, Garcia Foncillas J, Ray-Coquard I, Penault-Llorca F, Foulkes WD, Turnbull C, Hanson H, Narod S, Arun BK, Aapro MS, Mandel JL, Normanno N, Lambrechts D, Vergote I, Anahory M, Baertschi B, Baudry K, Bignon YJ, Bollet M, Corsini C, Cussenot O, De la Motte Rouge T, Duboys de Labarre M, Duchamp F, Duriez C, Fizazi K, Galibert V, Gladieff L, Gligorov J, Hammel P, Imbert-Bouteille M, Jacot W, Kogut-Kubiak T, Lamy PJ, Nambot S, Neuzillet Y, Olschwang S, Rebillard X, Rey JM, Rideau C, Spano JP, Thomas F, Treilleux I, Vandromme M, Vendrell J, Vintraud M, Zarca D, Hughes KS, Alés Martínez JE.
    • Eur J Cancer. 2021 Feb 9;146:30-47. doi: 10.1016/j.ejca.2020.12.023. Epub ahead of print.
    • Preliminary Screening for Hereditary Breast and Ovarian Cancer Using a Chatbot Augmented Intelligence Genetic Counselor: Development and Feasibility Study.
    • Sato A, Haneda E, Suganuma N, Narimatsu H.
    • JMIR Form Res. 2021 Feb 5;5(2):e25184. doi: 10.2196/25184.
    • Initiatives to Scale Up and Expand Reach of Cancer Genomic Services Outside of Specialty Clinical Settings: A Systematic Review.
    • Guan Y, McBride CM, Rogers H, Zhao J, Allen CG, Escoffery C.
    • Am J Prev Med. 2021 Feb;60(2):e85-e94. doi: 10.1016/j.amepre.2020.08.029. Epub 2020 Nov 7.
    • Review
    • Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing.
    • Hughes E, Tshiaba P, Wagner S, Judkins T, Rosenthal E, Roa B, Gallagher S, Meek S, Dalton K, Hedegard W, Adami CA, Grear DF, Domchek SM, Garber J, Lancaster JM, Weitzel JN, Kurian AW, Lanchbury JS, Gutin A, Robson ME.
    • JCO Precis Oncol. 2021 Jan 28;5:PO.20.00246. doi: 10.1200/PO.20.00246.
    • Increased ease of access to genetic counseling for low-income women with breast cancer using a point of care screening tool.
    • Rao SK, Thomas KA, Singh R, Biltibo E, Lammers PE, Wiesner GL.
    • J Community Genet. 2021 Jan 3. doi: 10.1007/s12687-020-00499-9. Epub ahead of print.
    • CanRisk Tool - A web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants.
    • Carver T, Hartley S, Lee A, Cunningham AP, Archer S, Babb de Villiers C, Roberts J, Ruston R, Walter FM, Tischkowitz M, Easton DF, Antoniou AC.
    • Cancer Epidemiol Biomarkers Prev. 2020 Dec 17:cebp.1319.2020. doi: 10.1158/1055-9965.EPI-20-1319. Epub ahead of print.
    • New Approach for Risk Estimation Algorithms of BRCA1/2 Negativeness Detection with Modelling Supervised Machine Learning Techniques.
    • Yazici H, Odemis DA, Aksu D, Erdogan OS, Tuncer SB, Avsar M, Kilic S, Turkcan GK, Celik B, Aydin MA.
    • Dis Markers. 2020 Dec 9;2020:8594090. doi: 10.1155/2020/8594090.
    • A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndrome.
    • Gao F, Pan X, Dodd-Eaton EB, Recio CV, Montierth MD, Bojadzieva J, Mai PL, Zelley K, Johnson VE, Braun D, Nichols KE, Garber JE, Savage SA, Strong LC, Wang W.
    • Genome Res. 2020 Aug 18. doi: 10.1101/gr.249599.119. Epub ahead of print.
    • Breast cancer risk assessment and management.
    • Masood S.
    • Breast J. 2020 Aug 11. doi: 10.1111/tbj.14013. Epub ahead of print.
    • Editorial
    • Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis.
    • Chen J, Bae E, Zhang L, Hughes K, Parmigiani G, Braun D, Rebbeck TR.
    • JNCI Cancer Spectr. 2020 Apr 23 [eCollection 2020 Aug.];4(4):pkaa029. doi: 10.1093/jncics/pkaa029.
    • Breast MRI texture analysis for prediction of BRCA-associated genetic risk.
    • Vasileiou G, Costa MJ, Long C, Wetzler IR, Hoyer J, Kraus C, Popp B, Emons J, Wunderle M, Wenkel E, Uder M, Beckmann MW, Jud SM, Fasching PA, Cavallaro A, Reis A, Hammon M.
    • BMC Med Imaging. 2020 Jul 29;20(1):86. doi: 10.1186/s12880-020-00483-2.
    • Breast cancer risk assessment and management programs: A practical guide.
    • Sciaraffa T, Guido B, Khan SA, Kulkarni S.
    • Breast J. 2020 Jul 14. doi: 10.1111/tbj.13967. Epub ahead of print.
    • Review
    • Improving primary care identification of familial breast cancer risk using proactive invitation and decision support.
    • Qureshi N, Dutton B, Weng S, Sheehan C, Chorley W, Robertson JFR, Kendrick D, Kai J.
    • Fam Cancer. 2020 Jun 11. doi: 10.1007/s10689-020-00188-z. Epub ahead of print.
    • Web-based return of BRCA2 research results: one-year genetic counselling experience in Iceland.
    • Stefansdottir V, Thorolfsdottir E, Hognason HB, Patch C, van El C, Hentze S, Cordier C, Mendes Á, Jonsson JJ.
    • Eur J Hum Genet. 2020 Jun 10. doi: 10.1038/s41431-020-0665-1. Epub ahead of print.
    • How to improve the identification of patients with cancer eligible for genetic counselling?
    • Bracci R, Gasperini B, Capalbo M, Campanelli T, Caimmi E, Mattioli R, Espinosa E, Prospero E.
    • Eur J Cancer Care (Engl). 2020 Jun 8:e13276. doi: 10.1111/ecc.13276. Epub ahead of print.
    • Practical implementation of frailty models in Mendelian risk prediction.
    • Huang T, Gorfine M, Hsu L, Parmigiani G, Braun D.
    • Genet Epidemiol. 2020 Jun 7. doi: 10.1002/gepi.22323. Epub ahead of print.
    • BFOR Study Uses Digital Tools to Facilitate Population BRCA Screening in Ashkenazi Jewish Community.
    • Anderson A.
    • Precision Oncology News. 2020 Jun 3.
    • Development and Pilot Implementation of the Genomic Risk Assessment for Cancer Implementation and Sustainment (GRACIAS) Intervention in Mexico.
    • Blazer KR, Chavarri-Guerra Y, Villarreal Garza C, Nehoray B, Mohar A, Daneri-Navarro A, Del Toro A, Aguilar D, Arteaga J, Álvarez RM, Mejia R, Herzog J, Castillo D, Fernandez M, Weitzel JN.
    • JCO Glob Oncol. 2021 Jun;7:992-1002. doi: 10.1200/GO.20.00587.
    • Executive Summary of the Early-Onset Breast Cancer Evidence Review Conference.
    • Chelmow D, Pearlman MD, Young A, Bozzuto L, Dayaratna S, Jeudy M, Kremer ME, Scott DM, O'Hara JS.
    • Obstet Gynecol. 2020 Jun;135(6):1457-1478. doi: 10.1097/AOG.0000000000003889.
    • Genetic Testing and Screening Recommendations for Patients with Hereditary Breast Cancer.
    • Bharucha PP, Chiu KE, François FM, Scott JL, Khorjekar GR, Tirada NP.
    • Radiographics. 2020 May 29:190181. doi: 10.1148/rg.2020190181. Epub ahead of print.
    • Review

    Related:

    Commentary:

    Invited Commentary: Breast Cancer Risk Assessment and Screening Strategies-What's New?

    • Utilization of health information technology among cancer genetic counselors.
    • Ritchie JB, Allen CG, Morrison H, Nichols M, Lauzon SD, Schiffman JD, Hughes Halbert C, Welch BM.
    • Mol Genet Genomic Med. 2020 May 28:e1315. doi: 10.1002/mgg3.1315. Epub ahead of print.
    • BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients.
    • Manchana T, Tantbirojn P, Pohthipornthawat N.
    • Gynecol Oncol Rep. 2020 May 27;33:100582. doi: 10.1016/j.gore.2020.100582.
    • Mutation prevalence tables for hereditary cancer derived from multi-gene panel testing.
    • Hart SN, Polley EC, Yussuf A, Yadav S, Goldgar DE, Hu C, LaDuca H, Smith LP, Fujimoto J, Li S, Couch FJ, Dolinsky JS.
    • Hum Mutat. 2020 May 22. doi: 10.1002/humu.24053. Epub ahead of print.
    • UMich Online Tool Aims to Improve Identification of Patients With Hereditary Cancer Risk.
    • Hu C.
    • GenomeWeb. 2020 May 19.
    • News
    • Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention.
    • Gaba F, Blyuss O, Liu X, Goyal S, Lahoti N, Chandrasekaran D, Kurzer M, Kalsi J, Sanderson S, Lanceley A, Ahmed M, Side L, Gentry-Maharaj A, Wallis Y, Wallace A, Waller J, Luccarini C, Yang X, Dennis J, Dunning A, Lee A, Antoniou AC, Legood R, Menon U, Jacobs I, Manchanda R.
    • Cancers (Basel). 2020 May 15;12(5):E1241. doi: 10.3390/cancers12051241.
    • Adventist Health, CancerIQ Collaboration Identifying More Patients for Guidelines-Supported Genetic Testing.
    • Versel N.
    • GenomeWeb. 2020 Apr 3.
    • News
    • Uptake of Risk Appropriate Behaviors After Breast Cancer Risk Stratification in the Mammography Screening Population.
    • Conley CC, Niell BL, Augusto BM, McIntyre M, Roetzheim R, Funaro K, Vadaparampil ST.
    • J Am Coll Radiol. 2020 Mar 27. pii: S1546-1440(20)30240-4. doi: 10.1016/j.jacr.2020.02.019. [Epub ahead of print]

    Related:

    Press: Mailed Notices of High Breast Cancer Risk Do Not Often Translate Into Behavior Changes. (Medscape/Reuters)

    • Updated Guideline Moves Genetic Testing Beyond BRCA.
    • Narozniak R.
    • OncologyLive. 2020 Mar 13;21(6).
    • News

    Related:

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Use of an Online Breast Cancer Risk Assessment and Patient Decision Aid in Primary Care Practices.
    • Eden KB, Ivlev I, Bensching KL, Franta G, Hersh AR, Case J, Fu R, Nelson HD.
    • J Womens Health (Larchmt). 2020 Mar 10. doi: 10.1089/jwh.2019.8143. [Epub ahead of print]
    • Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study.
    • Archer S, Babb de Villiers C, Scheibl F, Carver T, Hartley S, Lee A, Cunningham AP, Easton DF, McIntosh JG, Emery J, Tischkowitz M, Antoniou AC, Walter FM.
    • PLoS One. 2020 Mar 6;15(3):e0229999. doi: 10.1371/journal.pone.0229999. eCollection 2020.
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Recommendation Statement.
    • [No authors listed]
    • Am Fam Physician. 2020 Feb 15;101(4):233-238.

    Related:

    CME Activity:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.

    • Experts say more women should be tested for BRCA1 and BRCA2 genetic mutations.
    • Printz C.
    • Cancer. 2020 Feb 15;126(4):693. doi: 10.1002/cncr.32723.

    Related:

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers.
    • Weidner AE, Liggin ME, Zuniga BI, Tezak AL, Wiesner GL, Pal T.
    • Cancer. 2020 Jan 22. doi: 10.1002/cncr.32715. [Epub ahead of print]
    • Risk-based breast cancer screening strategies in women.
    • Harkness EF, Astley SM, Evans DG.
    • Best Pract Res Clin Obstet Gynaecol. 2019 Nov 18. pii: S1521-6934(19)30169-5. doi: 10.1016/j.bpobgyn.2019.11.005. [Epub ahead of print]
    • NorthBay Healthcare to Pilot GenomeSmart Genetic Test Recommendation Platform.
    • [No author given]
    • GenomeWeb. 2019 Nov 12.

    Related:

    Press: Startup GenomeSmart to Address Lack of Genetic Testing Knowledge With Digital Solution. (GenomeWeb)

    • Penetrance of different cancer types in families with Li-Fraumeni syndrome: a validation study using multi-center cohorts.
    • Shin SJ, Dodd-Eaton EB, Peng G, Bojadzieva J, Chen J, Amos CI, Frone MN, Khincha P, Mai PL, Savage SA, Ballinger ML, Thomas DM, Yuan Y, Strong LC, Wang W.
    • Cancer Res. 2019 Nov 12. pii: canres.0728.2019. doi: 10.1158/0008-5472.CAN-19-0728. [Epub ahead of print]
    • Genetic counselling and personalised risk assessment in the Australian pancreatic cancer screening program.
    • Dwarte T, McKay S, Johns A, Tucker K, Spigelman AD, Williams D, Stoita A.
    • Hered Cancer Clin Pract. 2019 Oct 23;17:30. doi: 10.1186/s13053-019-0129-1.
    • Performance of breast cancer risk assessment models in a large mammography cohort.
    • McCarthy AM, Guan Z, Welch M, Griffin ME, Sippo DA, Deng Z, Coopey SB, Acar A, Semine A, Parmigiani G, Braun D, Hughes KS.
    • J Natl Cancer Inst. 2019 Sep 26. pii: djz177. doi: 10.1093/jnci/djz177. [Epub ahead of print]

    Related:

    Editorial:

    Choosing Breast Cancer Risk Models: Importance of Independent Validation.

    • Choosing Breast Cancer Risk Models: Importance of Independent Validation.
    • Gail MH.
    • J Natl Cancer Inst. 2019 Sep 26. pii: djz180. doi: 10.1093/jnci/djz180. [Epub ahead of print]
    • STELO: a new tool for family physicians for the correct identification of inherited cancer syndromes.
    • Mariani C, Carnevali I, Lapi F, Paganini E, Civitelli C, Muzzolon J, Franzetti A, Guerroni A, Tibiletti MG.
    • Fam Pract. 2019 Sep 19. pii: cmz045. doi: 10.1093/fampra/cmz045. [Epub ahead of print]
    • Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model.
    • Terkelsen T, Christensen LL, Fenton DC, Jensen UB, Sunde L, Thomassen M, Skytte AB.
    • Fam Cancer. 2019 Aug 21. doi: 10.1007/s10689-019-00141-9. [Epub ahead of print]
    • Evaluation of a Clinical Decision Support System for the Prescription of Genetic Tests in the Gynecological Cancer Risk.
    • Moreno-Conde J, Alvarez-Romero C, Suárez-Mejías C, Martínez-Maestre MÁ, Silvan-Alfaro JM, Parra-Calderón CL.
    • Stud Health Technol Inform. 2019 Aug 21;264:704-708. doi: 10.3233/SHTI190314.
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    • US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB.
    • JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987.

    Related:

    Evidence report, Review:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Guidelines [Internet]:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    Editorial:

    Broadening Criteria for BRCA1/2 Evaluation: Placing the USPSTF Recommendation in Context.

    Editorial:

    USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.

    Editorial:

    Hereditary Cancer Evaluation in 2019-a Rapidly Evolving Landscape.

    Editorial:

    US Preventive Services Task Force Breast Cancer Recommendation Statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.

    News:

    USPSTF Calls for More BRCA Screening.

    Patient Page:

    Should I Be Tested for BRCA Mutations?

    Audio Interview, CME Activity: USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer. (JAMA)

    Press: USPSTF Recommendations on BRCA Mutation Testing. (Medscape Oncology)

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R.
    • JAMA. 2019 Aug 20;322(7):666-685. doi: 10.1001/jama.2019.8430.

    Related:

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    • Should I Be Tested for BRCA Mutations?
    • Jin J.
    • JAMA. 2019 Aug 20;322(7):702. doi: 10.1001/jama.2019.11251.

    Related:

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer.
    • Mangione CM.
    • JAMA. 2019 Aug 20.

    Related:

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R, Stillman L.
    • Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Aug. Report No.: 19-05251-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews.

    Related:

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    • Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan.
    • Hung FH, Wang YA, Jian JW, Peng HP, Hsieh LL, Hung CF, Yang MM, Yang AS.
    • Sci Rep. 2019 Jul 15;9(1):10229. doi: 10.1038/s41598-019-46707-6.
    • Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients.
    • Oliva L, Lozano R, Llácer C, Aragón I, Pajares BI, Sáez MI, Herrera-Imbroda B, Montesa A, Hernández D, Villatoro R, Otero A, Correa R, Grau G, Peinado P, Pacheco MI, García-Galisteo E, Rueda A, Machuca FJ, Alba E, Márquez-Aragonés A, Olmos D, Castro E.
    • Eur Urol Oncol. 2019 Jul 12. pii: S2588-9311(19)30100-2. doi: 10.1016/j.euo.2019.06.019. [Epub ahead of print]
    • Online Platform Helping Adventist Health Improve Breast Cancer Risk Assessment.
    • Versel N.
    • Precision Oncology News. Disease Areas. Cancer. 2019 Jun 7.
    • Press
    • Performance of the Gail and Tyrer-Cuzick breast cancer risk assessment models in women screened in a primary care setting with the FHS-7 questionnaire.
    • Vianna FSL, Giacomazzi J, Oliveira Netto CB, Nunes LN, Caleffi M, Ashton-Prolla P, Camey SA.
    • Genet Mol Biol. 2019 Jun 3. pii: S1415-47572019005018101. doi: 10.1590/1678-4685-GMB-2018-0110. [Epub ahead of print]
    • Breast Cancer Risk Prediction Models: Challenges in Clinical Application.
    • Paquin M, Fasolino T, Steck MB.
    • Clin J Oncol Nurs. 2019 Jun 1;23(3):256-259. doi: 10.1188/19.CJON.256-259.
    • Review
    • Evaluation of National Comprehensive Cancer Network guideline-based Tool for Risk Assessment for breast and ovarian Cancer (N-TRAC): A patient-reported survey for genetic high-risk assessment for breast and ovarian cancers in women.
    • Ozanne EM, Howe R, Mallinson D, Esserman L, Van't Veer LJ, Kaplan CP.
    • J Genet Couns. 2019 Jun;28(3):507-515. doi: 10.1002/jgc4.1051. Epub 2019 Jan 21.
    • Exploring genetic counselors' perceptions of usefulness and intentions to use refined risk models in clinical care based on the Technology Acceptance Model (TAM).
    • Heinlen C, Hovick SR, Brock GN, Klamer BG, Toland AE, Senter L.
    • J Genet Couns. 2019 Jun;28(3):664-672. doi: 10.1002/jgc4.1079. Epub 2019 Mar 7.
    • A systematic review and quality assessment of individualised breast cancer risk prediction models.
    • Louro J, Posso M, Hilton Boon M, Román M, Domingo L, Castells X, Sala M.
    • Br J Cancer. 2019 May 22. doi: 10.1038/s41416-019-0476-8. [Epub ahead of print]
    • Startup GenomeSmart to Address Lack of Genetic Testing Knowledge With Digital Solution.
    • Ray T.
    • GenomeWeb. 2019 May 20.

    Related:

    Press: NorthBay Healthcare to Pilot GenomeSmart Genetic Test Recommendation Platform. (GenomeWeb)

    • Effectiveness of interventions to identify and manage patients with familial cancer risk in primary care: a systematic review.
    • Lee SI, Patel M, Dutton B, Weng S, Luveta J, Qureshi N.
    • J Community Genet. 2019 May 6. doi: 10.1007/s12687-019-00419-6. [Epub ahead of print]
    • Review
    • Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
    • Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, Warren-Perry M, Eccleston A, Tan MM, Teo SH, Turner N, Strydom A, George A, Rahman N.
    • JAMA Netw Open. 2019 May 3;2(5):e194428. doi: 10.1001/jamanetworkopen.2019.4428.
    • A commentary on population genetic testing for primary prevention: changing landscape and the need to change paradigm.
    • Manchanda R, Gaba F.
    • BJOG. 2019 May;126(6):686-689. doi: 10.1111/1471-0528.15657.
    • Commentary
    • Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases.
    • Morgan RD, Burghel GJ, Flaum N, Bulman M, Clamp AR, Hasan J, Mitchell CL, Schlecht H, Woodward ER, Lallo FI, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Evans DGR.
    • J Med Genet. 2019 May;56(5):301-307. doi: 10.1136/jmedgenet-2018-105792. Epub 2019 Jan 25.
    • A randomized controlled intervention to promote readiness to genetic counseling for breast cancer survivors.
    • Kasting ML, Conley CC, Hoogland AI, Scherr CL, Kim J, Thapa R, Reblin M, Meade CD, Lee MC, Pal T, Quinn GP, Vadaparampil ST.
    • Psychooncology. 2019 May;28(5):980-988. doi: 10.1002/pon.5059. Epub 2019 Apr 11.
    • Quantifying risk stratification provided by diagnostic tests and risk predictions: Comparison to AUC and decision curve analysis.
    • Katki HA.
    • Stat Med. 2019 Apr 30. doi: 10.1002/sim.8163. [Epub ahead of print]
    • Uptake of genetic testing for germline BRCA1/2 pathogenic variants in a predominantly Hispanic population.
    • McGuinness JE, Trivedi MS, Silverman T, Marte A, Mata J, Kukafka R, Crew KD.
    • Cancer Genet. 2019 Apr 24. pii: S2210-7762(19)30059-6. doi: 10.1016/j.cancergen.2019.04.063. [Epub ahead of print]
    • Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms.
    • Bernstein-Molho R, Singer A, Laitman Y, Netzer I, Zalmanoviz S, Friedman E.
    • Breast Cancer Res Treat. 2019 Apr 12. doi: 10.1007/s10549-019-05228-6. [Epub ahead of print]
    • Hereditary Breast Cancer Risk Analysis in Uninsured Mexican-Origin Women Living in the U.S.-Mexico Border Region.
    • Salinas JJ, Roy R, Dwivedi AK, Shokar NK.
    • Hisp Health Care Int. 2019 Apr 12:1540415319837850. doi: 10.1177/1540415319837850. [Epub ahead of print]
    • Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort.
    • Rhiem K, Bücker-Nott HJ, Hellmich M, Fischer H, Ataseven B, Dittmer-Grabowski C, Latos K, Pelzer V, Seifert M, Schmidt A, Rezek D, Groh U, Meinerz W, Crommelinck D, Hahnen E, Wesselmann S, Schmutzler RK.
    • Breast J. 2019 Apr 5. doi: 10.1111/tbj.13257. [Epub ahead of print]
    • Impact of Implementing B-RSTTM to Screen for Hereditary Breast and Ovarian Cancer on Risk Perception and Genetic Counseling Uptake Among Women in an Academic Safety Net Hospital.
    • Wernke K, Bellcross C, Gabram S, Ali N, Stanislaw C.
    • Clin Breast Cancer. 2019 Mar 11. pii: S1526-8209(18)30730-4. doi: 10.1016/j.clbc.2019.02.014. [Epub ahead of print]
    • RE: Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.
    • Peshkin BN, Isaacs C, Schwartz MD.
    • J Natl Cancer Inst. 2019 Mar 5. pii: djz028. doi: 10.1093/jnci/djz028. [Epub ahead of print]

    Related:

    Letter, reply:

    Response to Peshkin, Isaacs, and Schwartz.

    Original research:

    Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.

    • BRCA Exchange Launches.
    • [No authors listed]
    • Cancer Discov. 2019 Mar;9(3):311-312. doi: 10.1158/2159-8290.CD-NB2019-008. Epub 2019 Jan 24.
    • News
    • Guidelines-Based Cancer Risk Assessment.
    • Forman A, Schwartz S.
    • Semin Oncol Nurs. 2019 Feb;35(1):34-46. doi: 10.1016/j.soncn.2018.12.010. Epub 2019 Jan 22.
    • BRCA mutation screening and patterns among high-risk Lebanese subjects.
    • Farra C, Dagher C, Badra R, Hammoud MS, Alameddine R, Awwad J, Seoud M, Abbas J, Boulos F, El Saghir N, Mukherji D.
    • Hered Cancer Clin Pract. 2019 Jan 18;17:4. doi: 10.1186/s13053-019-0105-9. eCollection 2019.
    • Validation of a digital identification tool for individuals at risk for hereditary cancer syndromes.
    • Bucheit L, Johansen Taber K, Ready K.
    • Hered Cancer Clin Pract. 2019 Jan 11;17:2. doi: 10.1186/s13053-018-0099-8. eCollection 2019.
    • Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.
    • Caswell-Jin JL, Zimmer AD, Stedden W, Kingham KE, Zhou AY, Kurian AW.
    • J Natl Cancer Inst. 2019 Jan 1;111(1):95-98. doi: 10.1093/jnci/djy147.

    Related:

    Letter, comment:

    RE: Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.

    Letter, reply:

    Response to Peshkin, Isaacs, and Schwartz.

    • Germline Genetics of Prostate Cancer: Time to Incorporate Genetics into Early Detection Tools.
    • Fantus RJ, Helfand BT.
    • Clin Chem. 2019 Jan;65(1):74-79. doi: 10.1373/clinchem.2018.286658. Epub 2018 Nov 20.
    • Validation of Version 3.0 of the Breast Cancer Genetics Referral Screening Tool (B-RST™).
    • Bellcross C, Hermstad A, Tallo C, Stanislaw C.
    • Genet Med. 2019 Jan;21(1):181-184. doi: 10.1038/s41436-018-0020-x. Epub 2018 May 8.
    • Clinicians' use of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey.
    • Brédart A, Kop JL, Antoniou AC, Cunningham AP, De Pauw A, Tischkowitz M, Ehrencrona H, Schmidt MK, Dolbeault S, Rhiem K, Easton DF, Devilee P, Stoppa-Lyonnet D, Schmutlzer R.
    • J Community Genet. 2019 Jan;10(1):61-71. doi: 10.1007/s12687-018-0362-8. Epub 2018 Mar 5.
    • An Applied Framework in Support of Shared Decision Making about BRCA Genetic Testing.
    • Silverman TB, Kuperman GJ, Vanegas A, Sin M, Dimond J, Crew KD, Kukafka R.
    • AMIA Annu Symp Proc. 2018 Dec 5;2018:961-969. eCollection 2018.
    • Automatic Genetic Risk Assessment Calculation Using Breast Cancer Family History Data from the EHR compared to Self-Report.
    • Sin M, McGuinness JE, Trivedi MS, Vanegas A, Silverman TB, Crew KD, Kukafka R.
    • AMIA Annu Symp Proc. 2018 Dec 5;2018:970-978. eCollection 2018.
    • BRCA1/2 mutations, including large genomic rearrangements, among unselected ovarian cancer patients in Korea.
    • Kim DH, Cho CH, Kwon SY, Ryoo NH, Jeon DS, Lee W, Ha JS.
    • J Gynecol Oncol. 2018 Nov;29(6):e90. doi: 10.3802/jgo.2018.29.e90.
    • Unusual recurrence of breast cancer in a BRCA-variant patient after fat grafting.
    • Skendelas JP, Lee C, Mangino A, Carson WE 3rd.
    • Clin Case Rep. 2018 Oct 31;6(12):2457-2462. doi: 10.1002/ccr3.1861. eCollection 2018 Dec.
    • Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial.
    • Kinney AY, Howell R, Ruckman R, McDougall JA, Boyce TW, Vicuña B, Lee JH, Guest DD, Rycroft R, Valverde PA, Gallegos KM, Meisner A, Wiggins CL, Stroup A, Paddock LE, Walters ST.
    • Contemp Clin Trials. 2018 Oct;73:123-135. doi: 10.1016/j.cct.2018.09.005. Epub 2018 Sep 18.
    • Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    • Hoyer J, Vasileiou G, Uebe S, Wunderle M, Kraus C, Fasching PA, Thiel CT, Hartmann A, Beckmann MW, Lux MP, Reis A.
    • BMC Cancer. 2018 Sep 26;18(1):926. doi: 10.1186/s12885-018-4821-8.
    • Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data.
    • Madsen T, Braun D, Peng G, Parmigiani G, Trippa L1.
    • Genet Epidemiol. 2018 Sep;42(6):528-538. doi: 10.1002/gepi.22130. Epub 2018 Jun 25.
    • Accuracy of Risk Prediction Models for Breast Cancer and BRCA1/BRCA2 Mutation Carrier Probabilities in Israel.
    • Kenan ES, Friger M, Shochat-Bigon D, Schayek H, Bernstein-Molho R, Friedman E.
    • Anticancer Res. 2018 Aug;38(8):4557-4563. doi: 10.21873/anticanres.12760.
    • The Pink Underside: The Commercialization of Medical Risk Assessment and Decision-Making Tools for Hereditary Breast Cancer Risk.
    • Hesse-Biber S, Flynn B, Farrelly K.
    • Qual Health Res. 2018 Aug;28(10):1523-1538. doi: 10.1177/1049732318767395. Epub 2018 Apr 11.
    • The impact of patient age on breast cancer risk prediction models.
    • Coopey SB, Acar A, Griffin M, Cintolo-Gonzalez J, Semine A, Hughes KS.
    • Breast J. 2018 Jul;24(4):592-598. doi: 10.1111/tbj.12976. Epub 2018 Jan 8.
    • Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia.
    • Lim KK, Yoon SY, Mohd Taib NA, Shabaruddin FH, Dahlui M, Woo YL, Thong MK, Teo SH, Chaiyakunapruk N.
    • Appl Health Econ Health Policy. 2018 Jun;16(3):395-406. doi: 10.1007/s40258-018-0384-8.
    • Increased centrosome number in BRCA-related breast cancer specimens determined by immunofluorescence analysis.
    • Watanabe G, Chiba N, Nomizu T, Furuta A, Sato K, Miyashita M, Tada H, Suzuki A, Ohuchi N, Ishida T.
    • Cancer Sci. 2018 Jun;109(6):2027-2035. doi: 10.1111/cas.13595. Epub 2018 May 15.
    • Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data.
    • Wunderle M, Olmes G, Nabieva N, Häberle L, Jud SM, Hein A, Rauh C, Hack CC, Erber R, Ekici AB, Hoyer J, Vasileiou G, Kraus C, Reis A, Hartmann A, Schulz-Wendtland R, Lux MP, Beckmann MW, Fasching PA.
    • Geburtshilfe Frauenheilkd. 2018 May;78(5):481-492. doi: 10.1055/a-0603-4350. Epub 2018 Jun 4.
    • Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.
    • Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, Olah E, Olopade OI, Solano AR, Teo SH, Thomassen M, Weitzel JN, Chan TL, Couch FJ, Goldgar DE, Kruse TA, Palmero EI, Park SK, Torres D, van Rensburg EJ, McGuffog L, Parsons MT, Leslie G, Aalfs CM, Abugattas J, Adlard J, Agata S, Aittomäki K, Andrews L, Andrulis IL, Arason A, Arnold N, Arun BK, Asseryanis E, Auerbach L, Azzollini J, Balmaña J, Barile M, Barkardottir RB, Barrowdale D, Benitez J, Berger A, Berger R, Blanco AM, Blazer KR, Blok MJ, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS, Caldes T, Caliebe A, Caligo MA, Campbell I, Caputo SM, Chiquette J, Chung WK, Claes KBM, Collée JM, Cook J, Davidson R, de la Hoya M, De Leeneer K, de Pauw A, Delnatte C, Diez O, Ding YC, Ditsch N, Domchek SM, Dorfling CM, Velazquez C, Dworniczak B, Eason J, Easton DF, Eeles R, Ehrencrona H, Ejlertsen B; EMBRACE, Engel C, Engert S, Evans DG, Faivre L, Feliubadaló L, Ferrer SF, Foretova L, Fowler J, Frost D, Galvão HCR, Ganz PA, Garber J, Gauthier-Villars M, Gehrig A; GEMO Study Collaborators, Gerdes AM, Gesta P, Giannini G, Giraud S, Glendon G, Godwin AK, Greene MH, Gronwald J, Gutierrez-Barrera A, Hahnen E, Hauke J; HEBON, Henderson A, Hentschel J, Hogervorst FBL, Honisch E, Imyanitov EN, Isaacs C, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Vijai J, Kaczmarek K, Karlan BY, Kast K, Investigators K, Kim SW, Konstantopoulou I, Korach J, Laitman Y, Lasa A, Lasset C, Lázaro C, Lee A, Lee MH, Lester J, Lesueur F, Liljegren A, Lindor NM, Longy M, Loud JT, Lu KH, Lubinski J, Machackova E, Manoukian S, Mari V, Martínez-Bouzas C, Matrai Z, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Mensenkamp AR, Mickys U, Miller A, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Neuhausen SL, Nevanlinna H, Ngeow J, Nguyen HP, Niederacher D, Nielsen HR, Nielsen FC, Nussbaum RL, Offit K, Öfverholm A, Ong KR, Osorio A, Papi L, Papp J, Pasini B, Pedersen IS, Peixoto A, Peruga N, Peterlongo P, Pohl E, Pradhan N, Prajzendanc K, Prieur F, Pujol P, Radice P, Ramus SJ, Rantala J, Rashid MU, Rhiem K, Robson M, Rodriguez GC, Rogers MT, Rudaitis V, Schmidt AY, Schmutzler RK, Senter L, Shah PD, Sharma P, Side LE, Simard J, Singer CF, Skytte AB, Slavin TP, Snape K, Sobol H, Southey M, Steele L, Steinemann D, Sukiennicki G, Sutter C, Szabo CI, Tan YY, Teixeira MR, Terry MB, Teulé A, Thomas A, Thull DL, Tischkowitz M, Tognazzo S, Toland AE, Topka S, Trainer AH, Tung N, van Asperen CJ, van der Hout AH, van der Kolk LE, van der Luijt RB, Van Heetvelde M, Varesco L, Varon-Mateeva R, Vega A, Villarreal-Garza C, von Wachenfeldt A, Walker L, Wang-Gohrke S, Wappenschmidt B, Weber BHF, Yannoukakos D, Yoon SY, Zanzottera C, Zidan J, Zorn KK, Hutten Selkirk CG, Hulick PJ, Chenevix-Trench G, Spurdle AB, Antoniou AC, Nathanson KL.
    • Hum Mutat. 2018 May;39(5):593-620. doi: 10.1002/humu.23406. Epub 2018 Mar 12.
    • Evaluation of the relative effectiveness of the 2017 updated Manchester scoring system for predicting BRCA1/2 mutations in a Southeast Asian country.
    • Chew W, Moorakonda RB, Courtney E, Soh H, Li ST, Chen Y, Shaw T, Allen JC, Evans DGR, Ngeow J.
    • J Med Genet. 2018 May;55(5):344-350. doi: 10.1136/jmedgenet-2017-105073. Epub 2017 Dec 23.
    • Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.
    • Swanson CL, Kumar A, Maharaj JM, Kemppainen JL, Thomas BC, Weinhold MR, Slaby KM, Mara KC, Wick MJ, Bakkum-Gamez JN.
    • Gynecol Oncol. 2018 Apr;149(1):121-126. doi: 10.1016/j.ygyno.2018.01.033. Epub 2018 Feb 3.
    • Molecular-genetic models for prognosis of development of tumors of reproductive system in women with family history of cancer.
    • Paliychuk OV, Polishchuk LZ, Rossokha ZI, Chekhun VF.
    • Exp Oncol. 2018 Mar;40(1):59-67.
    • Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
    • Grant RC, Holter S, Borgida A, Dhani NC, Hedley DW, Knox JJ, Akbari MR, Zogopoulos G, Gallinger S.
    • J Genet Couns. 2018 Feb 13. doi: 10.1007/s10897-018-0212-1. [Epub ahead of print]
    • Performance of BRCA1/2 mutation prediction models in male breast cancer patients.
    • Moghadasi S, Grundeken V, Janssen LAM, Dijkstra NH, Rodríguez-Girondo M, van Zelst-Stams WAG, Oosterwijk JC, Ausems MGEM, Oldenburg RA, Adank MA, Blom EW, Ruijs M, van Os TAM, van Deurzen CHM, Martens JWM, Schroder CP, Wijnen JT, Vreeswijk MPG, van Asperen CJ.
    • Clin Genet. 2018 Jan;93(1):52-59. doi: 10.1111/cge.13065. Epub 2017 Sep 25.
    • Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries.
    • Brédart A, Kop JL, Antoniou AC, Cunningham AP, De Pauw A, Tischkowitz M, Ehrencrona H, Dolbeault S, Robieux L, Rhiem K, Easton DF, Devilee P, Stoppa-Lyonnet D, Schmutlzer R.
    • Fam Cancer. 2018 Jan;17(1):31-41. doi: 10.1007/s10689-017-0014-x.
    • Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data.
    • Khiabanian H, Hirshfield KM, Goldfinger M, Bird S, Stein M, Aisner J, Toppmeyer D, Wong S, Chan N, Dhar K, Gheeya J, Vig H, Hadigol M, Pavlick D, Ansari S, Ali S, Xia B, Rodriguez-Rodriguez L, Ganesan S.
    • JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00148. Epub 2018 Jan 19.
    • Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
    • Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, Bose P, Ch'ng C, Reisle C, Eirew P, Corbett R, Mungall KL, Thiessen N, Ma Y, Schein JE, Mungall AJ, Zhao Y, Moore RA, Den Brok W, Wilson S, Villa D, Shenkier T, Lohrisch C, Chia S, Yip S, Gelmon K, Lim H, Renouf D, Sun S, Schrader KA, Young S, Bosdet I, Karsan A, Laskin J, Marra MA, Jones SJM.
    • Clin Cancer Res. 2017 Dec 15;23(24):7521-7530. doi: 10.1158/1078-0432.CCR-17-1941.
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Introduction. Models for Prediction of Breast and Gynecologic Cancer Risk.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. High-Penetrance Breast and/or Gynecologic Cancer Susceptibility Genes. BRCA1 and BRCA2. Clinical criteria and models for prediction of the likelihood of a BRCA1 or BRCA2 pathogenic variant.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    • Alemar B, Gregório C, Herzog J, Matzenbacher Bittar C, Brinckmann Oliveira Netto C, Artigalas O, D Schwartz IV, Coffa J, Alves Camey S, Weitzel J, Ashton-Prolla P.
    • PLoS One. 2017 Nov 21;12(11):e0187630. doi: 10.1371/journal.pone.0187630. eCollection 2017.
    • Predictability of BRCA1/2 mutation status in patients with ovarian cancer: How to select women for genetic testing in middle-income countries.
    • Teixeira N, Maistro S, Del Pilar Estevez Diz M, Mourits MJ, Oosterwijk JC, Folgueira MAK, de Bock GH.
    • Maturitas. 2017 Nov;105:113-118. doi: 10.1016/j.maturitas.2017.06.002. Epub 2017 Jun 4.
    • Cancer Status Bests Family History for BRCA Testing.
    • Neil Osterweil.
    • Medscape. Conference News. 2017 Oct 19.
    • Pathology update to the Manchester Scoring System based on testing in over 4000 families.
    • Evans DG, Harkness EF, Plaskocinska I, Wallace AJ, Clancy T, Woodward ER, Howell TA, Tischkowitz M, Lalloo F.
    • J Med Genet. 2017 Oct;54(10):674-681. doi: 10.1136/jmedgenet-2017-104584. Epub 2017 May 10.
    • Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.
    • Cintolo-Gonzalez JA, Braun D, Blackford AL, Mazzola E, Acar A, Plichta JK, Griffin M, Hughes KS.
    • Breast Cancer Res Treat. 2017 Jul;164(2):263-284. doi: 10.1007/s10549-017-4247-z. Epub 2017 Apr 25.
    • Review
    • Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women.
    • [No authors listed]
    • Obstet Gynecol. 2017 Jul;130(1):e1-e16. doi: 10.1097/AOG.0000000000002158.

    Related:

    Summary:

    Practice Bulletin No. 179 Summary: Breast Cancer Risk Assessment and Screening in Average-Risk Women.

    • Online self-test identifies women at high familial breast cancer risk in population-based breast cancer screening without inducing anxiety or distress.
    • van Erkelens A, Sie AS, Manders P, Visser A, Duijm LE, Mann RM, Ten Voorde M, Kroeze H, Prins JB, Hoogerbrugge N.
    • Eur J Cancer. 2017 Jun;78:45-52. doi: 10.1016/j.ejca.2017.03.014. Epub 2017 Apr 14.
    • Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer.
    • Masuda K, Hirasawa A, Irie-Kunitomi H, Akahane T, Ueki A, Kobayashi Y, Yamagami W, Nomura H, Kataoka F, Tominaga E, Banno K, Susumu N, Aoki D.
    • Jpn J Clin Oncol. 2017 May 1;47(5):401-406. doi: 10.1093/jjco/hyx019.
    • Breast Cancer Risk Assessment Models and High-Risk Screening.
    • Barke LD, Freivogel ME.
    • Radiol Clin North Am. 2017 May;55(3):457-474. doi: 10.1016/j.rcl.2016.12.013.
    • Review
    • Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral.
    • Rosenberger LH, Weber R, Sjoberg D, Vickers AJ, Mangino DA, Morrow M, Pilewskie ML.
    • Breast Cancer Res Treat. 2017 Apr;162(2):275-282. doi: 10.1007/s10549-017-4115-x. Epub 2017 Jan 28.
    • Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores.
    • Evans DG, Woodward ER, Howell SJ, Verhoef S, Howell A, Lalloo F.
    • Fam Cancer. 2017 Apr;16(2):173-179. doi: 10.1007/s10689-016-9942-0.
    • BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
    • Eoh KJ, Park JS, Park HS, Lee ST, Han J, Lee JY, Kim SW, Kim S, Kim YT, Nam EJ.
    • Gynecol Oncol. 2017 Apr;145(1):137-141. doi: 10.1016/j.ygyno.2017.01.026. Epub 2017 Feb 1.
    • Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
    • Antonucci I, Provenzano M, Sorino L, Balsamo M, Aceto GM, Battista P, Euhus D, Cianchetti E, Ballerini P, Natoli C, Palka G, Stuppia L.
    • J Hum Genet. 2017 Mar;62(3):379-387. doi: 10.1038/jhg.2016.138. Epub 2016 Dec 8.
    • Evaluating the performance of National Comprehensive Cancer Network (NCCN) breast and ovarian genetic/familial high risk assessment referral criteria for breast cancer women in an Asian surgical breast clinic.
    • Lim GH, Borje E, Allen JC Jr.
    • Gland Surg. 2017 Feb;6(1):35-42. doi: 10.21037/gs.2016.11.05.
    • Validation of an Efficient Screening Tool to Identify Low-Income Women at High Risk for Hereditary Breast Cancer.
    • Stewart SL, Kaplan CP, Lee R, Joseph G, Karliner L, Livaudais-Toman J, Pasick RJ.
    • Public Health Genomics. 2016 [2017 Jan;]19(6):342-351. doi: 10.1159/000452095. Epub 2016 Oct 28.
    • Computing Individual Risks Based on Family History in Genetic Disease in the Presence of Competing Risks.
    • Nuel G, Lefebvre A, Bouaziz O.
    • Comput Math Methods Med. 2017;2017:9193630. doi: 10.1155/2017/9193630. Epub 2017 Nov 9.
    • Learning Healthcare System for the Prescription of Genetic Testing in the Gynecological Cancer Risk.
    • Suárez-Mejías C, Martínez-García A, Martínez-Maestre MÁ, Silvan-Alfaro JM, Moreno Conde J, Parra-Calderón CL.
    • Stud Health Technol Inform. 2017;235:96-100.
    • Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.
    • Lee AJ, Cunningham AP, Tischkowitz M, Simard J, Pharoah PD, Easton DF, Antoniou AC.
    • Genet Med. 2016 Dec;18(12):1190-1198. doi: 10.1038/gim.2016.31. Epub 2016 Apr 14.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: PALB2 breast cancer recurrence

    Subject: article request

    • The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial.
    • Drescher CW, Beatty JD, Resta R, Andersen MR, Watabayashi K, Thorpe J, Hawley S, Purkey H, Chubak J, Hanson N, Buist DSM, Urban N.
    • Cancer. 2016 Nov 15;122(22):3509-3518. doi: 10.1002/cncr.30190. Epub 2016 Jul 22.
    • Assessing, Counseling, and Treating Patients at High Risk for Breast Cancer.
    • Clifford E, Hughes KS, Roberts M, Pirzadeh-Miller S, McLaughlin SA.
    • Ann Surg Oncol. 2016 Oct;23(10):3128-32. doi: 10.1245/s10434-016-5399-5. Epub 2016 Jul 11.
    • Review
    • Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients.
    • Jung J, Kang E, Gwak JM, Seo AN, Park SY, Lee AS, Baek H, Chae S, Kim EK, Kim SW.
    • Curr Oncol. 2016 Oct;23(5):298-303. Epub 2016 Oct 25.
    • A model for patient-direct screening and referral for familial cancer risk.
    • Niendorf KB, Geller MA, Vogel RI, Church TR, Leininger A, Bakke A, Madoff RD.
    • Fam Cancer. 2016 Oct;15(4):707-16. doi: 10.1007/s10689-016-9912-6.
    • Consensus Guideline on Hereditary Genetic Testing for Patients With and Without Breast Cancer
    • ASBS Research committee
    • The American Society of Breast Surgeons. www.breastsurgeons.org. 2016 Sep 13.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: American Society of Breast Surgeons Consenus Guidelines on Genetic Testing

    Subject: American Society of Breast Surgeons Consenus Guidelines on Genetic Testing

    • Contribution of extended family history in assessment of risk for breast and colon cancer.
    • Solomon BL, Whitman T, Wood ME.
    • BMC Fam Pract. 2016 Sep 1;17(1):126. doi: 10.1186/s12875-016-0521-0.
    • Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers.
    • Vos JR, Oosterwijk JC, Aalfs CM, Rookus MA, Adank MA, van der Hout AH, van Asperen CJ, Gómez Garcia EB, Mensenkamp AR, Jager A, Ausems MG, Mourits MJ, de Bock GH; Hereditary Breast and Ovarian Cancer Research Group Netherlands.
    • Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1251-8. doi: 10.1158/1055-9965.EPI-16-0182. Epub 2016 Jun 8.
    • Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study.
    • Evans DG, Astley S, Stavrinos P, Harkness E, Donnelly LS, Dawe S, Jacob I, Harvie M, Cuzick J, Brentnall A, Wilson M, Harrison F, Payne K, Howell A.
    • Southampton (UK): NIHR Journals Library; 2016 Aug.
    • Use of a Point-of-Care Tool to Improve Nurse Practitioner BRCA Knowledge.
    • Smania M.
    • Clin J Oncol Nurs. 2016 Jun 1;20(3):327-31. doi: 10.1188/16.CJON.327-331.
    • Fast Screen Identifies Women at Risk for Hereditary Cancers.
    • Ingrid Hein.
    • Medscape Medical News. Conference News. Oncology Nursing Society (ONS) 2016 Annual Congress. 2016 May 3.
    • KOHBRA BRCA risk calculator (KOHCal): a model for predicting BRCA1 and BRCA2 mutations in Korean breast cancer patients.
    • Kang E, Park SK, Lee JW, Kim Z, Noh WC, Jung Y, Yang JH, Jung SH, Kim SW.
    • J Hum Genet. 2016 May;61(5):365-71. doi: 10.1038/jhg.2015.164. Epub 2016 Jan 14.
    • Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing.
    • Elsayegh N, Barrera AM, Muse KI, Lin H, Kuerer HM, Helm M, Litton JK, Arun BK.
    • Front Genet. 2016 Apr 27;7:71. doi: 10.3389/fgene.2016.00071. eCollection 2016.
    • A targeted approach to genetic counseling in breast cancer patients: the experience of an Italian local project.
    • La Verde N, Corsi F, Moretti A, Peissel B, Dalu D, Girelli S, Fasola C, Gambaro A, Roversi G, Azzollini J, Radice P, Pensotti V, Farina G, Manoukian S.
    • Tumori. 2016 Feb 4;102(1):45-50. doi: 10.5301/tj.5000407. Epub 2015 Sep 10.
    • Breast cancer in high-risk Afrikaner families: Is BRCA founder mutation testing sufficient?
    • Seymour HJ, Wainstein T, Macaulay S, Haw T, Krause A.
    • S Afr Med J. 2016 Feb 3;106(3):264-7. doi: 10.7196/SAMJ.2016.v106i3.10285.
    • Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry.
    • Dite GS, MacInnis RJ, Bickerstaffe A, Dowty JG, Allman R, Apicella C, Milne RL, Tsimiklis H, Phillips KA, Giles GG, Terry MB, Southey MC, Hopper JL.
    • Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):359-65. doi: 10.1158/1055-9965.EPI-15-0838. Epub 2015 Dec 16.
    • Associations of Breast Cancer Risk Prediction Tools With Tumor Characteristics and Metastasis.
    • Holm J, Li J, Darabi H, Eklund M, Eriksson M, Humphreys K, Hall P, Czene K.
    • J Clin Oncol. 2016 Jan 20;34(3):251-8. doi: 10.1200/JCO.2015.63.0624. Epub 2015 Nov 30.
    • A two-stage approach to genetic risk assessment in primary care.
    • Biswas S, Atienza P, Chipman J, Blackford AL, Arun B, Hughes K, Parmigiani G.
    • Breast Cancer Res Treat. 2016 Jan;155(2):375-83. doi: 10.1007/s10549-016-3686-2. Epub 2016 Jan 19.
    • Breast Cancer Risk Assessment: Moving Beyond BRCA 1 and 2.
    • Scalia-Wilbur J, Colins BL, Penson RT, Dizon DS.
    • Semin Radiat Oncol. 2016 Jan;26(1):3-8. doi: 10.1016/j.semradonc.2015.09.004. Epub 2015 Sep 4.
    • Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information.
    • Kurian AW, Antoniou AC, Domchek SM.
    • Am Soc Clin Oncol Educ Book. 2016;35:44-56. doi: 10.14694/EDBK_158817.
    • BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia.
    • Mundhofir FE, Wulandari CE, Prajoko YW, Winarni TI.
    • Asian Pac J Cancer Prev. 2016;17(3):1539-46.
    • Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers.
    • Appel SJ, Cleiment RJ.
    • J Natl Black Nurses Assoc. 2015 Dec;26(2):17-26.
    • The readability of online breast cancer risk assessment tools.
    • Cortez S, Milbrandt M, Kaphingst K, James A, Colditz G.
    • Breast Cancer Res Treat. 2015 Nov;154(1):191-9.
    • A risk management model for familial breast cancer: A new application using Fuzzy Cognitive Map method.
    • Papageorgiou EI, Jayashree Subramanian, Karmegam A, Papandrianos N.
    • Comput Methods Programs Biomed. 2015 Nov;122(2):123-35. doi: 10.1016/j.cmpb.2015.07.003. Epub 2015 Jul 18.
    • Why Breast Cancer Risk by the Numbers Is Not Enough: Evaluation of a Decision Aid in Multi-Ethnic, Low-Numerate Women.
    • Kukafka R, Yi H, Xiao T, Thomas P, Aguirre A, Smalletz C, David R, Crew K.
    • J Med Internet Res. 2015 Jul 14;17(7):e165. doi: 10.2196/jmir.4028.
    • Can the breast screening appointment be used to provide risk assessment and prevention advice?
    • Evans DG, Howell A.
    • Breast Cancer Res. 2015 Jul 9;17(1):84. doi: 10.1186/s13058-015-0595-y.
    • Assessing absolute changes in breast cancer risk due to modifiable risk factors.
    • Quante AS, Herz J, Whittemore AS, Fischer C, Strauch K, Terry MB.
    • Breast Cancer Res Treat. 2015 Jul;152(1):193-7. doi: 10.1007/s10549-015-3411-6. Epub 2015 May 27.
    • RE: Combined Associations of Genetic and Environmental Risk Factors: Implications for Prevention of Breast Cancer.
    • Baker SG.
    • J Natl Cancer Inst. 2015 May 7;107(6). pii: djv127. doi: 10.1093/jnci/djv127. Print 2015 Jun.

    Related:

    Commentary

    Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer.

    • BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.
    • Mitri ZI, Jackson M, Garby C, Song J, Giordano SH, Hortobágyi GN, Singletary CN, Hashmi SS, Arun BK, Litton JK.
    • Oncologist. 2015 Jun;20(6):593-7. doi: 10.1634/theoncologist.2014-0425. Epub 2015 May 6.

    Related:

    Comment

    Male Breast Cancer: A Study in Small Steps.

    • Recent Enhancements to the Genetic Risk Prediction Model BRCAPRO.
    • Mazzola E, Blackford A, Parmigiani G, Biswas S.
    • Cancer Inform. 2015 May 10;14(Suppl 2):147-57. doi: 10.4137/CIN.S17292. eCollection 2015.
    • Association of family risk and lifestyle/comorbidities in ovarian cancer patients.
    • Teixeira N, Folgueira MA, Maistro S, Encinas G, Bock GH, Diz Mdel P.
    • Rev Assoc Med Bras. 2015 May-Jun;61(3):234-9. doi: 10.1590/1806-9282.61.03.234.
    • To Reflex or Not: Additional BRCA1/2 Testing in Ashkenazi Jewish Individuals Without Founder Mutations.
    • Petrucelli N, Mange S, Fulbright JL, Dohany L, Zakalik D, Duquette D.
    • J Genet Couns. 2015 Apr;24(2):285-293. Epub 2014 Sep 9.
    • Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability.
    • Berrino J, Berrino F, Francisci S, Peissel B, Azzollini J, Pensotti V, Radice P, Pasanisi P, Manoukian S.
    • Fam Cancer. 2015 Mar;14(1):117-28. doi: 10.1007/s10689-014-9766-8.
    • Population-based genetic risk prediction and stratification for ovarian cancer: views from women at high risk.
    • Rahman B, Meisel SF, Fraser L, Side L, Gessler S, Wardle J, Lanceley A.
    • Fam Cancer. 2015 Mar;14(1):135-44. doi: 10.1007/s10689-014-9769-5.
    • General practice and the Internet revolution. Use of an Internet social network to communicate information on prevention in France.
    • Veuillotte I, Morel G, Pitois S, Haler R, Mercier P, Aubry C, Cannet D.
    • Health Informatics J. 2015 Mar;21(1):3-9. doi: 10.1177/1460458213494905.
    • Personalized assessment and management of women at risk for breast cancer in North America.
    • Pruthi S, Heisey R, Bevers T.
    • Womens Health (Lond Engl). 2015 Mar;11(2):213-23; quiz 223-4. doi: 10.2217/whe.14.79.
    • Breast cancer risks and risk prediction models.
    • Engel C, Fischer C.
    • Breast Care (Basel). 2015 Feb;10(1):7-12. doi: 10.1159/000376600.
    • Genetic risk assessment for breast and gynecological malignancies.
    • Profato JL, Arun BK.
    • Curr Opin Obstet Gynecol. 2015 Feb;27(1):1-5. doi: 10.1097/GCO.0000000000000142.
    • Review
    • Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
    • Spurdle AB, Couch FJ, Parsons MT, McGuffog L, Barrowdale D, Bolla MK, Wang Q, Healey S, Schmutzler R, Wappenschmidt B, Rhiem K, Hahnen E, Engel C, Meindl A, Ditsch N, Arnold N, Plendl H, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Ellis S, Frost D, Platte R, Perkins J, Evans D, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Scuvera G, Manoukian S, Bonanni B, Mariette F, Fortuzzi S, Viel A, Pasini B, Papi L, Varesco L, Balleine R, Nathanson KL, Domchek SM, Offitt K, Jakubowska A, Lindor N, Thomassen M, Jensen U, Rantala J, Borg Å, Andrulis IL, Miron A, Hansen T, Caldes T, Neuhausen SL, Toland AE, Nevanlinna H, Montagna M, Garber J, Godwin AK, Osorio A, Factor RE, Terry MB, Rebbeck TR, Karlan BY, Southey M, Rashid M, Tung N, Pharoah P, Blows FM, Dunning AM, Provenzano E, Hall P, Czene K, Schmidt MK, Broeks A, Cornelissen S, Verhoef S, Fasching PA, Beckmann MW, Ekici AB, Slamon DJ, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Chang-Claude J, Flesch-Janys D, Rudolph A, Seibold P, Aittomäki K, Muranen TA, Heikkilä P, Blomqvist C, Figueroa J, Chanock SJ, Brinton L, Lissowska J, Olson JE, Pankratz VS, John EM, Whittemore AS, West DW, Hamann U, Torres D, Ulmer H, Rüdiger T, Devilee P, Tollenaar R, Seynaeve C, Van Asperen CJ, Eccles DM, Tapper WJ, Durcan L, Jones L, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Dwek M, Swann R, Bane AL, Glendon G, Mulligan AM, Giles GG, Milne RL, Baglietto L, McLean C, Carpenter J, Clarke C, Scott R, Brauch H, Brüning T, Ko YD, Cox A, Cross SS, Reed M, Lubinski J, Jaworska-Bieniek K, Durda K, Gronwald J, Dörk T, Bogdanova N, Park-Simon TW, Hillemanns P, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Burwinkel B, Marme F, Surovy H, Yang R, Anton-Culver H, Ziogas A, Hooning MJ, Collée J, Martens J, Tilanus-Linthorst M, Brenner H, Dieffenbach A, Arndt V, Stegmaier C, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Lindblom A, Margolin S, Joseph V, Robson M, Rau-Murthy R, González-Neira A, Arias J, Zamora P, Benítez J, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Peterlongo P, Zaffaroni D, Barile M, Capra F, Radice P, Teo SH, Easton DF, Antoniou AC, Chenevix-Trench G, Goldgar DE; ABCTB Investigators; EMBRACE Group; GENICA Network; HEBON Group; kConFab Investigators.
    • Breast Cancer Res. 2014 Dec 23;16(6):3419. doi: 10.1186/s13058-014-0474-y.
    • From observation to intervention: development of a psychoeducational intervention to increase uptake of BRCA genetic counseling among high-risk breast cancer survivors.
    • Vadaparampil ST, Malo TL, Nam KM, Nelson A, de la Cruz CZ, Quinn GP.
    • J Cancer Educ. 2014 Dec;29(4):709-19. doi: 10.1007/s13187-014-0643-9.
    • Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer.
    • Kast K, Schmutzler RK, Rhiem K, Kiechle M, Fischer C, Niederacher D, Arnold N, Grimm T, Speiser D, Schlegelberger B, Varga D, Horvath J, Beer M, Briest S, Meindl A, Engel C.
    • Int J Cancer. 2014 Nov 15;135(10):2352-61. doi: 10.1002/ijc.28875. Epub 2014 Apr 25.
    • Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
    • Zugazagoitia J, Pérez-Segura P, Manzano A, Blanco I, Vega A, Custodio A, Teulé A, Fachal L, Martínez B, González-Sarmiento R, Cruz-Hernández JJ, Chirivella I, Garcés V, Garre P, Romero A, Caldés T, Díaz-Rubio E, de la Hoya M.
    • Breast Cancer Res Treat. 2014 Nov;148(2):415-21. doi: 10.1007/s10549-014-3167-4. Epub 2014 Oct 24.
    • Genetics and BRCA in Primary Care.
    • Katherine Kolor.
    • Medscape Oncology, CDC Expert Commentary, 2014 Oct 13.
    • Can multiple SNP testing in BRCA2 and BRCA1 female carriers be used to improve risk prediction models in conjunction with clinical assessment?
    • Prosperi MC, Ingham SL, Howell A, Lalloo F, Buchan IE, Evans DG.
    • BMC Med Inform Decis Mak. 2014 Oct 1;14:87. doi: 10.1186/1472-6947-14-87.
    • Implementing a screening tool for identifying patients at risk for hereditary breast and ovarian cancer: a statewide initiative.
    • Brannon Traxler L, Martin ML, Kerber AS, Bellcross CA, Crane BE, Green V, Matthews R, Paris NM, Gabram SG.
    • Ann Surg Oncol. 2014 Oct;21(10):3342-7. doi: 10.1245/s10434-014-3921-1. Epub 2014 Jul 22.

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Article Request

    • Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study.
    • Gierach GL, Li H, Loud JT, Greene MH, Chow CK, Lan L, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, Mai PL, Galbo CE, Nichols K, Calzone KA, Olopade OI, Gail MH, Giger ML.
    • Breast Cancer Res. 2014;16(4):424. doi: 10.1186/PREACCEPT-1744229618121391. Epub 2014 Aug 23.
    • Recent BRCAPRO Upgrades Significantly Improve Calibration.
    • Mazzola E, Chipman J, Cheng SC, Parmigiani G.
    • Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1689-95. doi: 10.1158/1055-9965.EPI-13-1364. Epub 2014 Jun 2.
    • A randomized, controlled trial to increase discussion of breast cancer in primary care.
    • Kaplan CP, Livaudais-Toman J, Tice JA, Kerlikowske K, Gregorich SE, Pérez-Stable EJ, Pasick RJ, Chen A, Quinn J, Karliner LS.
    • Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1245-53. doi: 10.1158/1055-9965.EPI-13-1380. Epub 2014 Apr 24.
    • Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families.
    • Arnold AG, Otegbeye E, Fleischut MH, Glogowski EA, Siegel B, Boyar SR, Salo-Mullen E, Amoroso K, Sheehan M, Berliner JL, Stadler ZK, Kauff ND, Offit K, Robson ME, Zhang L.
    • Breast Cancer Res Treat. 2014 Jun;145(3):625-34. doi: 10.1007/s10549-014-2987-6. Epub 2014 May 14.
    • Short-term outcomes of the implementation of a computer-based breast cancer risk assessment program during screening mammography.
    • Ray D, Grumet S, Lagmay-Fuentes P, Jacob L, Terzo A, Puma A, Hwang S.
    • J Community Support Oncol. 2014 Jun;12(6):209-11.
    • Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.
    • Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG; Northwestern Cancer Genetics Group.
    • Cancer. 2014 May 15;120(10):1557-64. doi: 10.1002/cncr.28577. Epub 2014 Feb 12.
    • Tools of the trade: individualized breast cancer risk assessment.
    • Millstine D, David P, Pruthi S.
    • J Womens Health (Larchmt). 2014 May;23(5):434-6. doi: 10.1089/jwh.2014.4761. Epub 2014 Apr 7.
    • Underestimation of Risk of a BRCA1 or BRCA2 Mutation in Women With High-Grade Serous Ovarian Cancer by BRCAPRO: A Multi-Institution Study.
    • Daniels MS, Babb SA, King RH, Urbauer DL, Batte BA, Brandt AC, Amos CI, Buchanan AH, Mutch DG, Lu KH.
    • J Clin Oncol. 2014 Apr 20;32(12):1249-55. doi: 10.1200/JCO.2013.50.6055. Epub 2014 Mar 17.

    Related:

    Comment/Letter:

    Misreported family histories and underestimation of risk.

    Comment/Letter:

    Reply to D. Braun et al.

    • Let’s Talk About Risk: Personalizing Breast Cancer Risk Prediction.
    • [No author given]
    • Show Me The Evidence, Canadian Institute of Health Research, 2014 Spring.
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation.
    • Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R.
    • Ann Intern Med. 2014 Feb 18;160(4):255-66.
    • Assessing the Genetic Risk for BRCA-Related Breast or Ovarian Cancer in Women: Recommendations From the U.S. Preventive Services Task Force.
    • [No authors listed]
    • Ann Intern Med. 2014 Feb 18;160(4). doi: 10.7326/P14-9008.

    Related:

    Systematic Review:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation.

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement.
    • Moyer VA; U.S. Preventive Services Task Force.
    • Ann Intern Med. 2014 Feb 18;160(4):271-81.

    Related:

    Patient Education Handout:

    Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.

    • Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    • [No authors listed]
    • Ann Intern Med. 2014 Feb 18;160(4):I-16.

    Related:

    Practice Guideline:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement.

    • A new scoring system in cancer genetics: application to criteria for BRCA1 and BRCA2 mutation screening.
    • Bonaïti B, Alarcon F, Andrieu N, Bonadona V, Dondon MG, Pennec S, Stoppa-Lyonnet D, Bonaïti-Pellié C, Perdry H.
    • J Med Genet. 2014 Feb;51(2):114-21. doi: 10.1136/jmedgenet-2013-101674. Epub 2013 Dec 16.

    Related:

    Free Full Text: A new scoring system in cancer genetics: application to criteria for BRCA1 and BRCA2 mutation screening. (Medscape Oncology)

    • BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.
    • Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC.
    • Br J Cancer. 2014 Jan 21;110(2):535-45. doi: 10.1038/bjc.2013.730. Epub 2013 Dec 17.
    • U.S. Preventive Services Task Force Finds Benefit in Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer for Small Group of High-Risk Women.
    • [No author given]
    • Yale Cancer Genetic Counseling. 2014 Jan 2.
    • Cancer risk communication, predictive testing and management in France, Germany, the Netherlands and the UK: general practitioners' and breast surgeons' current practice and preferred practice responsibilities.
    • Nippert I, Julian-Reynier C, Harris H, Evans G, van Asperen CJ, Tibben A, Schmidtke J.
    • J Community Genet. 2014 Jan;5(1):69-79. doi: 10.1007/s12687-013-0173-x. Epub 2013 Dec 3.
    • Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: A retrospective study in a sample of Italian cancer genetics clinics.
    • Varesco L, Viassolo V, Viel A, Gismondi V, Radice P, Montagna M, Alducci E, Della Puppa L, Oliani C, Tommasi S, Caligo MA, Vivanet C, Zuradelli M, Mandich P, Tibiletti MG, Cavalli P, Lucci Cordisco E, Turchetti D, Boggiani D, Bracci R, Bruzzi P, Bonelli L.
    • Breast. 2013 Dec;22(6):1130-5. doi: 10.1016/j.breast.2013.07.053. Epub 2013 Sep 5.
    • Self administered screening for hereditary cancers in conjunction with mammography and ultrasound.
    • McDonnell CH, Seidenwurm DJ, McDonnell DE, Bobolis KA.
    • Fam Cancer. 2013 Dec;12(4):651-6. doi: 10.1007/s10689-013-9641-z.
    • Breast cancer risk prediction accuracy in Jewish Israeli high-risk women using the BOADICEA and IBIS risk models.
    • Laitman Y, Simeonov M, Keinan-Boker L, Liphshitz I, Friedman E.
    • Genet Res (Camb). 2013 Dec;95(6):174-7. doi: 10.1017/S0016672313000232. Epub 2014 Feb 10.
    • Prognosis of probability of BRCA1 and BRCA2 mutations carriage in women with compromised family history of breast and/or ovarian cancer.
    • Rybchenko LA, Bychkova AM, Skyban GV, Klymenko SV.
    • Probl Radiac Med Radiobiol. 2013 Sep;18:253-260.
    • Breast Cancer Risk Factors.
    • Alison T Stopeck.
    • eMedicine. 2013 Aug 19.
    • Communicating risk of hereditary breast and ovarian cancer with an interactive decision support tool.
    • Rupert DJ, Squiers LB, Renaud JM, Whitehead NS, Osborn RJ, Furberg RD, Squire CM, Tzeng JP.
    • Patient Educ Couns. 2013 Aug;92(2):188-96. doi: 10.1016/j.pec.2013.04.008. Epub 2013 May 9.
    • Improving the management of people with a family history of breast cancer in primary care: before and after study of audit-based education.
    • Rafi I, Chowdhury S, Chan T, Jubber I, Tahir M, de Lusignan S.
    • BMC Fam Pract. 2013 Jul 24;14:105. doi: 10.1186/1471-2296-14-105.
    • Providing access to risk prediction tools via the HL7 XML-formatted risk web service.
    • Chipman J, Drohan B, Blackford A, Parmigiani G, Hughes K, Bosinoff P.
    • Breast Cancer Res Treat. 2013 Jul;140(1):187-93. doi: 10.1007/s10549-013-2605-z. Epub 2013 Jun 23.
    • Simplifying clinical use of the genetic risk prediction model BRCAPRO.
    • Biswas S, Atienza P, Chipman J, Hughes K, Barrera AM, Amos CI, Arun B, Parmigiani G.
    • Breast Cancer Res Treat. 2013 Jun;139(2):571-9. doi: 10.1007/s10549-013-2564-4. Epub 2013 May 21.
    • Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
    • Fischer C, Kuchenbäcker K, Engel C, Zachariae S, Rhiem K, Meindl A, Rahner N, Dikow N, Plendl H, Debatin I, Grimm T, Gadzicki D, Flöttmann R, Horvath J, Schröck E, Stock F, Schäfer D, Schwaab I, Kartsonaki C, Mavaddat N, Schlegelberger B, Antoniou AC, Schmutzler R; German Consortium for Hereditary Breast and Ovarian Cancer.
    • J Med Genet. 2013 Jun;50(6):360-7. doi: 10.1136/jmedgenet-2012-101415. Epub 2013 Apr 6.
    • The effectiveness of a graphical presentation in addition to a frequency format in the context of familial breast cancer risk communication: a multicenter controlled trial.
    • Henneman L, Oosterwijk JC, van Asperen CJ, Menko FH, Ockhuysen-Vermey CF, Kostense PJ, Claassen L, Timmermans DR.
    • BMC Med Inform Decis Mak. 2013 Apr 29;13:55. doi: 10.1186/1472-6947-13-55.
    • BRCA-1 and BRCA-2 mutation bedside detection and breast cancer clinical primary prevention.
    • Stagnaro S, Caramel S.
    • Front Genet. 2013 Mar 26;4:39. doi: 10.3389/fgene.2013.00039. eCollection 2013.
    • Improving mutation notification when new genetic information is identified in research: a trial of two strategies in familial breast cancer.
    • Wakefield CE, Thorne H, Kirk J, Niedermayr E, Doolan EL, Tucker K.
    • Genet Med. 2013 Mar;15(3):187-94. doi: 10.1038/gim.2012.115. Epub 2012 Sep 13.
    • Determination of Molecular Markers for BRCA1 and BRCA2 Heterozygosity Using Gene Expression Profiling.
    • Salmon AY, Salmon-Divon M, Zahavi T, Barash Y, Levy-Drummer RS, Jacob-Hirsch J, Peretz T.
    • Cancer Prev Res (Phila). 2013 Feb;6(2):82-90. doi: 10.1158/1940-6207.CAPR-12-0105. Epub 2013 Jan 22.

    Related:

    Research News:

    New test predicts BRCA1 and BRCA2 mutations.

    Press: The Future of BRCA1/BRCA2 Testing. (OncLive)

    • Legal liability and the uncertain nature of risk prediction: the case of breast cancer risk prediction models.
    • Black L, Knoppers BM, Avard D, Simard J.
    • Public Health Genomics. [2012 Nov;]15(6):335-40. doi: 10.1159/000342138. Epub 2012 Sep 12.
    • Accuracy of BRCA1/2 mutation prediction models in Korean breast cancer patients.
    • Kang E, Park SK, Yang JJ, Park B, Lee MH, Lee JW, Suh YJ, Lee JE, Kim HA, Oh SJ, Kim SW; Korean Breast Cancer Society.
    • Breast Cancer Res Treat. 2012 Aug;134(3):1189-97. doi: 10.1007/s10549-012-2022-8. Epub 2012 Mar 22.
    • Hereditary breast and ovarian cancer and other hereditary syndromes: using technology to identify carriers.
    • Drohan B, Roche CA, Cusack JC Jr, Hughes KS.
    • Ann Surg Oncol. 2012 Jun;19(6):1732-7. doi: 10.1245/s10434-012-2257-y. Epub 2012 Mar 17.
    • Review
    • Validation of three BRCA1/2 mutation-carrier probability models Myriad, BRCAPRO and BOADICEA in a population-based series of 183 German families.
    • Schneegans SM, Rosenberger A, Engel U, Sander M, Emons G, Shoukier M.
    • Fam Cancer. 2012 Jun;11(2):181-8. doi: 10.1007/s10689-011-9498-y.
    • Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO.
    • Biswas S, Tankhiwale N, Blackford A, Barrera AM, Ready K, Lu K, Amos CI, Parmigiani G, Arun B.
    • Breast Cancer Res Treat. 2012 May;133(1):347-55. doi: 10.1007/s10549-012-1958-z. Epub 2012 Jan 21.
    • Clinical software development for the Web: lessons learned from the BOADICEA project.
    • Cunningham AP, Antoniou AC, Easton DF.
    • BMC Med Inform Decis Mak. 2012 Apr 10;12:30. doi: 10.1186/1472-6947-12-30.
    • Efficient identification and referral of low-income women at high risk for hereditary breast cancer: a practice-based approach.
    • Joseph G, Kaplan C, Luce J, Lee R, Stewart S, Guerra C, Pasick R.
    • Public Health Genomics. [2012 Apr;]15(3-4):172-80. doi: 10.1159/000336419. Epub 2012 Apr 4.
    • Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort.
    • Kwong A, Wong CH, Suen DT, Co M, Kurian AW, West DW, Ford JM.
    • World J Surg. 2012 Apr;36(4):702-13. doi: 10.1007/s00268-011-1406-y.
    • Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.
    • Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B.
    • Cancer. 2012 Mar 15;118(6):1515-22. doi: 10.1002/cncr.26428. Epub 2011 Aug 25.

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Does anyone have a good reference for the occurence of DCIS in hereditary cancer syndromes?

    • Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer.
    • Ståhlbom AK, Johansson H, Liljegren A, von Wachenfeldt A, Arver B.
    • Fam Cancer. 2012 Mar;11(1):33-40. doi: 10.1007/s10689-011-9495-1.
    • Role of micronucleus test in predicting breast cancer susceptibility: a systematic review and meta-analysis.
    • Cardinale F, Bruzzi P, Bolognesi C.
    • Br J Cancer. 2012 Feb 14;106(4):780-90. doi: 10.1038/bjc.2011.567. Epub 2011 Dec 20.